[go: up one dir, main page]

WO2020243729A1 - Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t - Google Patents

Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Download PDF

Info

Publication number
WO2020243729A1
WO2020243729A1 PCT/US2020/035618 US2020035618W WO2020243729A1 WO 2020243729 A1 WO2020243729 A1 WO 2020243729A1 US 2020035618 W US2020035618 W US 2020035618W WO 2020243729 A1 WO2020243729 A1 WO 2020243729A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
seq
time period
period sufficient
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/035618
Other languages
English (en)
Inventor
Catherine Mary BOLLARD
Patrick Hanley
Christopher LAZARSKI
Michael Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Priority to EP20814747.0A priority Critical patent/EP3976068A4/fr
Publication of WO2020243729A1 publication Critical patent/WO2020243729A1/fr
Priority to US17/537,816 priority patent/US20220160767A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture.
  • the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines (or functional fragments or variants thereof).
  • the disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.
  • VSTs virus-specific T cells
  • Adoptive immunotherapy with virus-specific T cells therefore can be an alternative and effective way to treat viral infections that lack any effective treatment options.
  • T cells specific to coronavirus antigens, specifically antigens from SARS-CoV-2 can be an alternative and effective way to treat COVID- 19.
  • Manufacture of viral specific T cell products expands a heterogeneous pool of pre existing memory T cells from donor peripheral blood within in vitro culture vessels, with the final product containing a polyclonal mixture of CD4+ helper and CD8+ cytotoxic T cells. This diversity in their composition increases the complexity of their manufacture, as CD4+ T cells and CD8+ T cells can respond differently to cytokine stimulation.
  • IL-4 has been shown to enhance survival of resting T cells and induce CD4+ Th2 helper differentiation [4-6]
  • IL-15 promotes survival and diversity of CD8+ memory T cells [7,8]
  • Other examples include IL-6, which has been proposed to enhance Thl7 development [9], IL-7, which promotes T cell homeostatic survival [10-12], and IL-21, which also promotes the activity of CD8+ T cells and formation or maintenance of central memory [13-15]
  • IL-2 is a canonical T cell growth cytokine, which continues to be used in clinical trials due to its demonstrated effectiveness in expanding T cells derived from tumor infiltrating lymphocytes [16]
  • Our previous manufacturing methods have transitioned from culturing T cells in 24 well plates with IL-2 and APC transduced with viral antigens [17,18] to a simplified culture containing a combination of IL-4 and IL-7 in G-Rex gas permeable vessels with soluble mixes of peptides [3,19,20] This culture system has
  • the disclosure relates to certain cytokine compositions as well as the same compositions that induce or stimulate growth and proliferation of CD4+ and CD8+ T cell subpopulations after exposure for a time period sufficient to induce the growth or proliferation.
  • the method allows for a scientist to choose how and when to grow more cytotoxic T cells instead of helper CD4+ T cells. Essentially, this allows one of ordinary skill to toggle between CD4 and CD8 dominance by choosing a different cytokine mixture, which ultimately creates T cell products of different compositions. Additional advantages of the disclosed method and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice of the disclosed methods and compositions.
  • the disclosure also relates to a tissue culture system comprising a plurality of lymphocytes positioned within at least one vessel, cell culture media and a composition comprising at least two cytokines from Table 1 or functional fragments or variants thereof, wherein the functional fragments thereof or the variants thereof comprises at least about 75% sequence identity to the sequences identified in Table 1.
  • the disclosure relates to a method of selectively growing memory effector T cells from a cell composition comprising naive T cells comprising: contacting one or plurality of lymphocytes comprising the naive T cells with at least two peptides or nucleic acids encoding peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identify to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
  • the disclosure relates to a method of selectively growing memory effector T cells from a cell composition comprising naive T cells comprising: contacting one or plurality of lymphocytes comprising the naive T cells with at least two peptides or nucleic acids encoding peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to human IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to human IL-18, IL-15, IL-6, IL-7, IL-4, functional fragments or variants thereof for a time period sufficient to stimulate growth and proliferation of the one
  • the disclosure also relates to a method of inducing an antigen-specific immune response against a viral antigen, the method comprising: (a) contacting one or plurality of lymphocytes with at least two peptides or nucleic acids encoding peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identify to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to IL-18, IL-15, IL-6, IL-7, IL-4, functional fragments or variants thereof for a time period sufficient to stimulate growth and proliferation of the one or plurality of CD4+ and/
  • the viral antigen is from a virus of the family Coronaviridae. In some embodiments, the viral antigen is from a coronavirus. In some embodiments, the viral antigen comprises at least a portion of a coronavirus membrane protein. In some embodiments, the viral antigen comprises at least a portion of a coronavirus envelope protein. In some embodiments, the viral antigen comprises at least a portion of a coronavirus spike protein. In some embodiments, the viral antigen comprises at least a portion of a coronavirus nucleocapsid protein. In some embodiments, the viral antigen is from SARS-CoV- 2. In some embodiments, the viral antigen comprises at least a portion of SARS-CoV-2 membrane protein.
  • the viral antigen comprises at least a portion of SARS-CoV-2 envelope protein. In some embodiments, the viral antigen comprises at least a portion of SARS-CoV-2 spike protein. In some embodiments, the viral antigen comprises at least a portion of SARS-CoV-2 nucleocapsid protein.
  • the disclosure further relates to a method of generating, culturing and/or manufacturing CD4+ and/or CD8+ effector memory cells comprising: contacting one or plurality of lymphocytes with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to IL-18, IL-15, IL-6, IL-7, IL-4, functional fragments or variants thereof for a time period sufficient to stimulate growth and proliferation of the one or plurality of CD4+ and/or CD8+ T cells within the composition of
  • the disclosure further relates to a method of generating, culturing and/or manufacturing CD4+ and/or CD8+ effector memory cells comprising: contacting one or plurality of lymphocytes with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to human IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%,
  • the disclosure relates to a method of expanding a population of CD4+ and/or CD8+ memory effector T cells in a composition of cultured cells comprising contacting one or plurality of lymphocytes with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%,
  • the disclosure relates to a method of expanding a population of CD4+ and/or CD8+ memory effector T cells in a composition of cultured cells comprising contacting one or plurality of lymphocytes with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to human IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to human IL-18, IL-15, IL-6, IL-7, IL-4, functional fragments or variants thereof for a time period sufficient to stimulate growth and proliferation of the one or pluralit of CD4+ and/or CD8+ T cells within the
  • the disclosure relates to a method of culturing a composition comprising a population of one or a plurality of T cells comprising contacting the one or plurality of T cells with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
  • the disclosure relates to a method of culturing a composition comprising a population of one or a plurality of T cells comprising contacting the one or plurality of T cells with at least two peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity' to human IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality' of vectors that encode at least two peptides that comprise at least about 70%, 80%, 85%, 90%,
  • the disclosure also relates to a T cell composition comprising from about 2% to about 23% CD4+ and/or CD8+ memory effector cells manufactured or grown from a population of naive T cells or lymphocytes by any of the disclosed methods provided herein.
  • the disclosure further relates to a tissue culture system comprising: lymphocytes from a subject, cell culture media, and a composition comprising at least two polypeptide or nucleic acid encoding peptides chosen from a polypeptide that comprises at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identify to IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two polypeptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
  • the disclosure also relates to a T cell composition comprising from about 2% to about 23% CD4+ and/or CD8+ memory effector cells manufactured or grown from a population of naive T cells or lymphocytes by any of the disclosed methods provided herein.
  • the disclosure further relates to a tissue culture system comprising: lymphocytes from a subject, cell culture media, and a composition comprising at least two polypeptide or nucleic acid encoding peptides chosen from a polypeptide that comprises at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identify' to human IL-18, IL-15, IL-6, IL-7, IL-4 or functional fragments or variants thereof; or one or a plurality of vectors that encode at least two polypeptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
  • any of the disclosed methods further comprise wherein the one or plurality of T cells are nai ve prior to step of contacting and the one or plurality of T cells are CCR7+ CD45RO+ after performing the step of contacting.
  • the disclosure relates to methods of treating a Coronaviridae infection comprising administering one or a plurality of compositions comprising a therapeutically effective amount of T cells of the disclosure stimulated with: one or a plurality of cytokine compositions disclosed herein; and/or one or a plurality of viral antigens that comprise from about 70% to about 100% sequence identify to SEQ ID: 11, 12, 13, and/or 14, or antigen fragments thereof.
  • the Coronaviridae infection is a COVID-19 infection.
  • the disclosure also relates to a method of treatment, wherein the step of administering comprises intravenous or parentenal administration injection of cells.
  • FIG. 1 depicts the experimental design described in Example 1.
  • Peripheral blood was collected from consenting donors and cells were purified by Ficoll gradient isolation. 1 x 10 5 cells were plated in each well on Day 0 with CMV peptide pools (IE1 and pp65) and the indicated cytokine concentration alone or in combination. On Day 7, plates were split equally into fresh media and with fresh cytokines. On Day 10, plates were re-stimulated with or without additional peptides for 6 hours, fixed, and stained for phenotype (CD3, CD56, CD4, CD8), viability, and effector cytokine secretion (IFNy, TNFa).
  • phenotype CD3, CD56, CD4, CD8
  • IFNy effector cytokine secretion
  • FIG. 2A, 2B, 2C and 2D depict the plate layouts described in Example 1.
  • 1 x 10 5 cells were plated in each well on Day 0 with CMV peptide pools encompassing IE1 and pp65 and the indicated cytokine concentration alone or in combination for plate layout 3 (FIG. 2A).
  • plates were split equally into fresh media and with fresh cytokines.
  • plates were re-stimulated with or without peptides for 6 hours, fixed, and stained for phenotype (CD3,
  • CD56, CD4, CD8 CD56, CD4, CD8, viability, and effector cytokine secretion (IFNy, TNFa).
  • FIG. 3 depicts the gating strategy described in Example 1.
  • a representative sample was analyzed in Flowjo for staining and gating of effector lymphocyte populations.
  • Cells were separated from debris by gating forward scatter vs. side scatter.
  • Viable cells were identified by low staining of Live Dead viability dye.
  • T cells were identified by CD3+ staining, and effector subsets were subsequently characterized by CD4+ vs CD8+ staining.
  • Cells were then evaluated for cytokine production after culture with peptide pools by comparing staining of IFNy and TNFa with wells cultured in media alone.
  • FIG. 4 depicts a summary of representative heat map data obtained from the screening of additional cytokine combinations described in Example 1.
  • 1 x 10 5 cells from Sample 3 and Sample 4 were plated in each well on Day 0 with CMV peptide pools encompassing IE1 and pp65 and the indicated cytokine alone or in combination for plate layout 3.
  • Cells were analyzed for the total count of viable CD3+ T cells and the frequency of effector cytokine secretion over background (IFNy, TNFa).
  • FIG. 5A and 5B depict identification of superior cytokine combinations via high throughput flow cytometry analysis.
  • FIG. 5A Quantifications of phenotype and function of two plates from Sample 4 were analyzed by flow cytometry on Day 10, with entire contents of wells collected and visualized by heat map. The total count of viable CD3+ T cells were quantified from wells re-stimulated with media alone. The frequency of IFNy+ CD3+ cells was derived from the frequency of IFNy+ CD3+ cells after re-stimulation with IE1 and pp65 peptide pools and subtracted from media alone control wells.
  • FIG. 5B Wells containing the highest concentration of cytokines were compared between Samples 1-4 when cultured using plate layouts 1 and 2. The total recovered viable CD3+ count and the frequency of CMV specific CD3+ IFNy+ cells (n > 8) was compared across each sample.
  • FIG. 6A, 6B and 6C show that culture in IL15 and IL6 stimulates expansion of CMV specific CD3+ T cells equal or better than IL4 and IL7.
  • Cells were re-stimulated with CMV peptide pools for 6 hours and evaluated for phenotype and function by flow cytometry, with entire well contents analyzed for the top dilutions of IL15 and IL6, IL4 and IL7, IL15 alone, and no cytokine controls.
  • the total count of viable CD3+ T cells, the percentage of viability of all CD3+ cells, and viable CD56+ CD3- NK cell count were calculated from wells and shown in FIG. 6A.
  • the median total count of viable CD3+ CD4+ cells, CD3+ CD8+ cells, and the ratio of CD4+/CD8+ cells were calculated from wells and shown in FIG. 6B.
  • the median frequency of CD3+ IFNy+ cells and CD3+ IFNy+ TNFa+ cells were calculated from wells and shown in FIG. 6C, and the frequency of IFNy+ cells within CD4+ CD3+ and CD8+ CD3+ subtypes were analyzed.
  • FIG. 7A, 7B, 7C and 7D shown that T cell therapy products are effector memory in phenotype (CCR7- CD45RO+).
  • Cells were analyzed for the expression of memory markers CCR7 and CD45RO and divided into four populations both pre and post-culture with cytokines.
  • the pre-culture memory phenotype of viable cells was quantified for all samples (FIG. 7A) according to the layout presented for representative Sample 1 (FIG. 7B).
  • samples were analyzed again for memory markers CCR7 and CD45RO and averaged samples cultured in IL15/IL6 and IL4/IL7 growth conditions (FIG. 7C) and analyzed using 2-way ANOVA with Tukey’s correction (* corresponds to p ⁇ 0.05).
  • One representative sample was examined for the memory phenotype of CD3+ cells which were positive or negative for IFNy after re-stimulation with CMV specific peptides (FIG. 7D).
  • FIG. 8A and 8B shown that cells cultured in Grex-10 vessels with IL15/IL6 produce equivalent levels of IFNy compared with culture in IL4/IL7.
  • Cells were grown in Grex-10 culture vessels with IL15 and IL6 or IL4 and IL7 for 10 days and tested in ELISPOT assays for IFNy production when re-stimulated with media alone, actin (1 pg/mL), IE1 and pp65 peptide pools (1 pg/mL). or SEB (0.5 pg/mL).
  • a representative sample is given in FIG. 8A and the mean of four different samples was compared using 2-way ANOVA with Tukey’s correction (FIG. 8B). *** p ⁇ 0.001; **** p ⁇ 0.0001.
  • FIG. 9 depicts short amino acid sequences from viruses used in the production of amino acid mixes exposed to the cells of the disclosure.
  • FIG. 10A, 10B, IOC, 10D and 10E show T-cell recognition of SARS-CoV-2 viral antigens.
  • FIG. 10E Phenotype of the expanded cells was accessed by flow cytometry with markers for T-cells (CD3, CD4, CD8, TCRab, TCRgd), NK cells (CD16/CD56), and B-cells (CD 19).
  • FIG. 11A, 11B, llC and 11D show T-cell recognition of epitopes within membrane protein.
  • FIG. 11A T-cell epitope mapping of membrane protein was performed using 17 mini pools containing 5-12 peptides each, with responses measured via IFN-g ELISpot (SFC: spot forming units).
  • FIG. 11AB Epitope mapping identified responses to four peptides within AA 145-173 and 192-222 of the C-terminal intravirion domain. Intracellular cytokine staining demonstrated a predominant CD4-mediated response to membrane peptides 37-38 (FIG. 11C) as well as peptides 44-45 (FIG. 11D).
  • SEB staphylococcal enterotoxin beta.
  • FIG. 12A and 12B show clinical characteristics of convalescent COVID-19 patients.
  • FIG. 12A Flow diagram of illness severity (based on WHO classifications), T-cell and antibody immune response to SARS-CoV-2, and basis of COVID-19 diagnosis.
  • FIG. 12B Ribbon diagram of primary clinical symptoms of the 23 convalescent patients, as well as timing of PCR testing and research evaluation.
  • FIG. 13A and 13B show SARS-CoV-2 antibody testing of normal controls and convalescent patients. Testing for antibodies to nucleocapsid (FIG. 13A) and spike proteins (FIG. 13B) was performed via luciferase immunoprecipitation assay. Positivity thresholds (dotted lines) were set based on previous data using unexposed normal control samples.
  • FIG. 14A and 14B show T-cell extended phenotyping of coronavirus-specific T-cells.
  • FIG. 14A T-cell populations following expansion were determined via flow cytometry. T-cells were classified as naive (CD45RO-/CCR7+/CD95-), central memory
  • FIG. 14AB Gating strategy for T-cell memory /naive subsets.
  • FIG. 15 shows detection of T-cell responses to SARS CoV-2 proteins from peripheral blood.
  • Peripheral blood mononuclear cells PBMC
  • convalescent patients triangles
  • unexposed controls circles
  • results are reported as spot forming colonies (SFC) per lxlO 5 cells per well.
  • PBMC alone and actin stimulation were utilized as negative controls.
  • Peptide libraries from cytomegalovirus pp65 and IE1 as well as adenovirus hexon and penton were utilized as additional viral controls.
  • FIG. 16 shows T-cell responses to SARS-CoV-2 versus illness severity in convalescent patients.
  • Expanded coronavirus-specific T-cells were tested for specificity to SARS-CoV-2 structural protein libraries on day 10 of culture via IFN-g ELISpot. Control unexposed donors (circles) and convalescent patients with mild disease (upward triangles) or moderate to severe disease (downward triangles) by WHO criteria were tested. Expanded cells alone (CTL alone) and actin stimulated cells were used as negative controls. Results are reported as spot forming colonies (SFC) per lxl 0 5 cells/well.
  • SFC spot forming colonies
  • FIG. 17 shows that wells containing the highest concentration of cytokines were compared between Samples 1-4 when cultured using plate layouts 1 and 2.
  • the average total count of viable CD3+ T cells, the viability of all CD3+ cells, and average viable CD56+ CD3- NK cell count were calculated from wells and shown in FIG. 18A.
  • the average total count of viable CD3+ CD4+ cells, CD3+ CD8+ cells, and the ratio of CD4+/CD8+ cells were calculated from wells and shown in FIG. 18B.
  • the average frequency of CD3+ IFNy+ cells and CD3+ IFNy+ TNFa+ cells were calculated from wells and shown in FIG. 18A and analyzed.
  • FIG. 19 shows 1 x 10 5 cells from Sample 3 and Sample 4 were plated in each well on Day 0 with CMV peptides IE1 and pp65 and the indicated cytokine concentration alone or in combination for plate layout 3. Cells were analyzed for the total count of viable CD3+ T cells and the frequency of effector cytokine secretion over background (IFNy, TNFa).
  • the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
  • values are expressed as approximations, by use of the antecedent“about,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise.
  • a reference to“A and/or B,” when used in conjunction with open-ended language such as“comprising” can refer, in some embodiments, to A without B (optionally including elements other than B); in another embodiments, to B without A (optionally including elements other than A); in yet another embodiments, to both A and B (optionally including other elements); etc.
  • “or” should he understood to have the same meaning as“and/or” as defined above.
  • “or” or“and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as“only one of’ or“exactly one of,” or, when used in the claims,“consisting of,” will refer to the inclusion of exactly one element of a number or list of elements.
  • antigenic determinants such as peptides with lengths of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or more amino acid residues that bind to major histocompatibility complex (MHC) molecules, form parts of MHC Class I or II complexes, or that are recognized when complexed with such molecules.
  • MHC major histocompatibility complex
  • the terms“activate,”“stimulate,”“enhance”“increase” and/or“induce” are used interchangeably to generally refer to the act of improving or increasing, either directly or indirectly, a concentration, level, function, activity, or behavior relative to the natural, expected, or average, or relative to a control condition.
  • “Activate” in context of an immunotherapy refers to a primary response induced by ligation of a cell surface moiety.
  • such stimulation entails the ligation of a receptor and a subsequent signal transduction event. Further, the stimulation event may activate a cell and upregulate or downregulate expression or secretion of a molecule.
  • activating CD8+ T cells or CD 8+ T cell activation refer to a process (e.g. , a signaling event) causing or resulting in one or more cellular responses of a CD8+ T cell (CTL), selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers.
  • CTL CD8+ T cell
  • an “activated CD8+ T cell” refers to a CD8+ T cell that has received an activating signal, and thus demonstrates one or more cellular responses, selected from proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. Suitable assays to measure CD8+ T cell activation are known in the art and are described herein.
  • allogeneic refers to medical therapy in which the donor and recipient are different individuals of the same species.
  • autologous refers to medical therapy in which the donor and recipient are the same person.
  • Coding sequence or“encoding nucleic acid” as used herein refers to a nucleic acid (RNA, DNA, or RNA/DNA hybrid molecule) that comprises a nucleotide sequence which encodes a protein.
  • the coding sequence may further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of an individual or mammal to whom the nucleic acid is administered.
  • “Complement” or“complementary” as used herein may mean a nucleic acid may mean Watson-Crick (e.g., A-T/U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules.
  • cytokine as used herein has its normal meaning in the art.
  • Non-limiting examples of cytokines used in the disclosure include interleukin-2 (IL-2), IL-4, IL-6, IL-7, IL- 12, IL-15, IL-18, IL-21 and IL-27.
  • cytotoxic T cell or“cytotoxic T lymphocyte” as used herein is a ty pe of immune cell that bears a CD8+ antigen and that can kill certain cells, including foreign cells, tumor cells, and cells infected with a virus. Cytotoxic T cells can be separated from other blood cells, grown ex vivo, and then given to a patient to kill tumor or viral cells.
  • a cytotoxic T cell is a type of white blood cell and a type of lymphocyte.
  • DC dendritic cell
  • effector cell describes a cell that can bind to or otherwise recognize an antigen and mediate an immune response.
  • Tumor-, vims-, or other antigen-specific T cells and NKT cells are examples of effector cells.
  • endogenous refers to any material from or produced inside an organism, cell, tissue or system.
  • epitopope or“antigenic determinant” as used herein refers to the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells.
  • exogenous refers to any material introduced from or produced outside an organism, cell, tissue or system.
  • a functional fragment means any portion of a polypeptide that is of a sufficient length to retain at least partial biological function that is similar to or substantially similar to the wild-type polypeptide upon which the fragment is based.
  • a functional fragment of a polypeptide is a polypeptide that comprises or possesses at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to any polypeptides disclosed in Table 1 and has sufficient length to retain at least partial binding affinity to one or a plurality of ligands that bind to the polypeptides in Table 1.
  • a functional fragment of a nucleic acid is a nucleic acid that comprises or possesses at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to any nucleic acid to which it is being compared and has sufficient length to retain at least partial function related to the nucleic acid to which it is being compared.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 10, about 20, about 30, about 40, about 50 , about 60, about 70, about 80, about 90, or about 100 contiguous amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 50 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 100 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 150 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed m Table 1 and has a length of at least about 200 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 300 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 350 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 400 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 450 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 550 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 600 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 650 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 700 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 800 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 850 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 900 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 950 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 1000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 1050 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 1250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 1500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 1750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 2000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 2250 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 2500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 2750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of at least about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 10, about 20, about 30, about 40, about 50 , about 60, about 70, about 80, about 90, or about 100 contiguous amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 50 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 100 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 150 ammo acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 200 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 300 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 350 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 400 ammo acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 450 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 550 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 600 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 650 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 700 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 800 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 850 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 900 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 950 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 1000 ammo acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 1050 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 1250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 1500 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 1750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 2000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 2250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 2500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 2750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length of no more than about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 2750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 2500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 2250 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 2000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 1750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 1500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 1250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 1000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 950 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 850 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 800 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 750 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 700 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 650 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 600 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 550 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 500 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 450 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 400 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 350 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 300 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 250 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 200 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 150 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 100 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 90 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 80 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 70 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 60 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 50 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 40 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 30 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 20 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 10 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 20 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 30 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 40 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 50 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 60 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 70 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 80 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 90 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 100 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 150 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 200 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 250 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 300 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 350 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 400 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 450 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 500 to about 3000 ammo acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 550 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 600 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 650 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 700 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 750 to about 3000 ammo acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 800 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 850 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 900 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 950 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 1000 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 1050 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 1250 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 1500 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 1750 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 2000 to about 3000 amino acids.
  • the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 2250 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 2500 to about 3000 amino acids. In some embodiments, the fragment is a fragment of any polypeptide disclosed in Table 1 and has a length from about 2750 to about 3000 amino acids.
  • heterologous refers to a nucleic acid sequence that is operably linked to another nucleic acid sequence to which it is not operably linked in nature, or to which it is operably linked at a different location in nature.
  • a protein-coding nucleic acid sequence operably linked to a promoter which is not the native promoter of this protein-coding sequence is considered to be heterologous to the promoter.
  • the heterologous sequence comprises a plasmid or episome.
  • A“naive” T cell or other immune effector cell as used herein is one that has not been exposed to or primed by an antigen or to an antigen-presenting cell presenting a peptide antigen capable of activating that cell.
  • non-engineered when referring to the cells of the compositions means a cell that does not contain or express an exogenous nucleic acid or amino acid sequence.
  • the cells of the compositions do not express, for example, a chimeric antigen receptor.
  • A“peptide library” or“overlapping peptide library” as used herein within the meaning of the application is a complex mixture of peptides which in the aggregate covers the partial or complete sequence of a protein antigen. Successive peptides within the mixture overlap each other, for example, a peptide library may be constituted of peptides 15 amino acids in length which overlapping adjacent peptides in the library by 11 amino acid residues and which span the entire length of a protein antigen. Peptide libraries may be commercially available or may be custom-made for particular antigens.
  • A“peripheral blood mononuclear cell” or“PBMC” as used herein is any peripheral blood cell having a round nucleus. These cells consist of lymphocytes (T cells, B-cells, NK cells) and monocytes. In humans, lymphocytes make up the majority of the PBMC population, followed by monocytes, and a small percentage of dendritic cells.
  • a“T cell precursor cell” can differentiate into a T cell and a“dendritic precursor cell” can differentiate into a dendritic cell.
  • A“T cell population” or“T cell subpopulation” can include thymocytes, immature T- lymphocytes, mature T-lymphocytes, resting T-lymphocytes and activated T-lymphocytes.
  • the T cell population or subpopulation can include ab T cells, including CD4+ T cells, CD8+ T cells, gd T cells, Natural Killer T cells, or any other subset of T cells.
  • phrases“pharmaceutically acceptable” refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
  • the term“pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • compositions are administered with at least one pharmaceutically acceptable carrier.
  • compositions or vehicle suitable for administering compositions of the present disclosure to subjects.
  • the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be“acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include, but not limited to, sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic cellulose,
  • Suitable pharmaceutical carriers are described in“Remington’s Pharmaceutical Sciences” by E. W. Martin, which is incorporated herein by reference in its entirety.
  • the pharmaceutically acceptable carrier is sterile and pyrogen- free water.
  • the pharmaceutically acceptable carrier is Ringer’s Lactate, sometimes known as lactated Ringer’s solution.
  • Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • sequence identity As used herein,“sequence identity,”“percent identity” or“percent homology” of two polynucleotide or two polypeptide sequences is determined by comparing the sequences using the GAP computer program (a part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters. “Identical” or“identity” as used herein in the context of two or more nucleic acids or amino acid sequences, may mean that the sequences have a specified percentage of residues that are the same over a specified region.
  • the percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity.
  • the residues of single sequence are included in the denominator but not the numerator of the calculation.
  • BLAST high scoring sequence pair
  • T is referred to as the neighborhood word score threshold (Altschul et al., supra).
  • the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached.
  • the Blast algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
  • the Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff et al., Proc. Natl. Acad. Sci.
  • a nucleic acid is considered similar to another if the smallest sum probability in comparison of the test nucleic acid to the other nucleic acid is less than about 1, less than about 0.1, less than about 0.01, and less than about 0.001.
  • Two single-stranded polynucleotides are “the complement” of each other if their sequences can be aligned in an anti-parallel orientation such that every nucleotide in one polynucleotide is opposite its complementary nucleotide in the other polynucleotide, without the introduction of gaps, and without unpaired nucleotides at the 5’ or the 3’ end of either sequence.
  • a polynucleotide is“complementary” to another polynucleotide if the two polynucleotides can hybridize to one another under moderately stringent conditions.
  • a polynucleotide can be complementary to another polynucleotide without being its complement.
  • the term“subject” is used throughout the specification to describe an animal from which a cell sample is taken or an animal to which a disclosed cell or nucleic acid sequences have been administered.
  • the animal is a human.
  • the term“patient” may be interchangeably used.
  • the term “patient” will refer to human patients suffering from a particular disease or disorder.
  • the subject may be a human suspected of having or being identified as at risk to develop cancer of the blood.
  • the subject may be diagnosed as having cancer of the blood or being identified as at risk to develop cancer of the blood.
  • the subject is suspected of having or has been diagnosed with requiring a bone marrow transplant.
  • the subject may be a human suspected of having or being identified as at risk to develop bone marrow transplants.
  • the subject may be a mammal which functions as a source of the endothelial cell sample.
  • the subject may be a non-human animal from which an endothelial cell sample is isolated or provided.
  • the term“mammal” encompasses both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, caprines, and porcines.
  • Nucleic acid or“oligonucleotide” or“polynucleotide” as used herein may mean at least two nucleotides covalently linked together.
  • the depiction of a single strand also defines the sequence of the complementary strand.
  • a nucleic acid also encompasses the complementary strand of a depicted single strand.
  • Many variants of a nucleic acid may be used for the same purpose as a given nucleic acid.
  • a nucleic acid also encompasses substantially identical nucleic acids and complements thereof.
  • a single strand provides a probe that may hybridize to a target sequence under stnngent hybridization conditions.
  • nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.
  • Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequence.
  • the nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine.
  • Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods. In some embodiments, the nucleic acid is isolated from an organism.
  • “Operably linked” as used herein may mean that expression of a gene is under the control of a promoter with which it is spatially connected.
  • a promoter may be positioned 5’ (upstream) or 3’ (downstream) of a gene under its control.
  • the distance between the promoter and a gene may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function.
  • Promoter may mean a synthetic or naturally-derived molecule which is capable of conferring, activating or enhancing expression of a nucleic acid in a cell.
  • a promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and/or to alter the spatial expression and/or temporal expression of same.
  • a promoter may also comprise distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.
  • a promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals.
  • a promoter may regulate the expression of a gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents.
  • promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and the CMV IE promoter.
  • polypeptide “peptide” and“protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-natural amino acids or chemical groups that are not amino acids.
  • the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
  • amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
  • the terms“purified” and“isolated” when used in the context of a compound or agent (including proteinaceous agents such as antibodies and polypeptides) that can be obtained from a natural source, e.g., cells refers to a compound or agent which is substantially free of contaminating materials from the natural source, e.g., soil particles, minerals, chemicals from the environment, and/or cellular materials from the natural source, such as but not limited to cell debris, cell wall materials, membranes, organelles, the bulk of the nucleic acids, carbohydrates, proteins, and/or lipids present in cells.
  • phrases“substantially free of natural source materials” refers to preparations of a compound or agent that has been separated from the material (e.g., cellular components of the cells) from which it is isolated.
  • a compound or agent that is isolated includes preparations of a compound or agent having less than about 30%, 20%, 10%, 5%, 2%, or 1% (by dry weight) of cellular materials and/or contaminating materials.
  • an“isolated” nucleic acid sequence or nucleotide sequence is one which is separated from other nucleic acid molecules which are present in a natural source of the nucleic acid sequence or nucleotide sequence.
  • an“isolated”, nucleic acid sequence or nucleotide sequence, such as a cDNA molecule can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors when chemically synthesized.
  • an“isolated” nucleic acid sequence or nucleotide sequence is a nucleic acid sequence or nucleotide sequence that is recombinantly expressed in a heterologous cell.
  • Stringent hybridization conditions may mean conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids. Stringent conditions are sequence- dependent and will be different in different circumstances. Stringent conditions may be selected to be about 5-10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm may be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50%> of the probes are occupied at equilibrium).
  • Tm thermal melting point
  • Stringent conditions may be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., about 10-50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal may be at least 2 to 10 times background hybridization.
  • Exemplary stringent hybridization conditions include the following: 50%> formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.
  • hybridization or“hybridizes” as used herein refers to the formation of a duplex between nucleotide sequences that are sufficiently complementary to form duplexes via Watson-Crick base pairing. Two nucleotide sequences are“complementary” to one another when those molecules share base pair organization homology. “Complementary” nucleotide sequences will combine with specificity to form a stable duplex under appropriate hybridization conditions.
  • two sequences need not have perfect homology to be“complementary.” Usually two sequences are sufficiently
  • “Substantially complementary" as used herein may mean that a first sequence is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the complement of a second sequence over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more nucleotides or amino acids, or that the two sequences hybridize under stringent hybridization conditions.
  • “Substantially identical” as used herein may mean that, in respect to a first and a second sequence, a first and second sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 1000 or more nucleotides or amino acids, or with respect to nucleic acids, if the first sequence is substantially complementary to the complement of the second sequence.
  • therapeutic effect as used herein is meant to refer to some extent of relief of one or more of the symptoms of a disorder (e.g., SARS-CoV-2 infection) or its associated pathology.
  • A“therapeutically effective amount” as used herein is meant to refer to an amount of an agent which is effective, upon single or multiple dose administration (such as a first, second and/or third booster) to the cell or subject, in prolonging the survivability of the patient with such a disorder, reducing one or more signs or symptoms of the disorder, preventing or delaying, and the like beyond that expected in the absence of such treatment.
  • A“therapeutically effective amount” is intended to qualify the amount required to achieve a therapeutic effect.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the “therapeutically effective amount” (e.g., ED50) of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the present disclosure employed in a pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • the therapeutically effective amount may be initially determined from preliminary in vitro studies and/or animal models.
  • a therapeutically effective dose may also be determined from human data.
  • the applied dose can be adjusted based on the relative bioavailability and potency of the administered agent. Adjusting the dose to achieve maximal efficacy based on the methods described above and other well-known methods is within the capabilities of the ordinarily skilled artisan.
  • General principles for determining therapeutic effectiveness which may be found in Chapter 1 of Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill (New York) (2001), incorporated herein by reference, are summarized below.
  • Drug products are considered to be pharmaceutical equivalents if they contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration. Two pharmaceutically equivalent dmg products are considered to be bioequivalent when the rates and extents of bioavailability of the active ingredient in the two products are not significantly different under suitable test conditions.
  • the terms“treat,”“treated,”“treating,”“treatment,” and the like as used herein are meant to refer to reducing or ameliorating a disorder and/or symptoms associated therewith (e.g., a viral infection).
  • the terms“treat,” “treated,”“treating,”“treatment,” and the like refer to the beneficial effects that a subject derives from a therapy, such as, but not limited to, the reduction or inhibition of the progression, spread and/or duration of a disease or disorder, the reduction or amelioration of the severity of a disease or disorder, amelioration of one or more symptoms of a disease or disorder, and/or the reduction in the duration of one or more symptom of a disease or disorder resulting from the
  • such terms in the context of viral infection include, but are not limited to, one, two, or three or more results following the administration of a therapy to a subject: (1) a reduction in the growth of virus in the body by measuring serum levels of virus; (2) a reduction in the number of virus-bearing cells; (3) an eradication, removal, or control of cell number expressing virus; (4) a reduction in mortality; (5) an increase in survival rate; (6) an increase in length of survival; (7) an increase in the number of patients with latent viral infection; (8) a decrease in hospitalization rate; (9) a decrease in hospitalization lengths; and (10) the maintenance in the numbers of virus in serum so that it does not increase by more than 10%, or by more than 8%, or by more than 6%, or by more than 4%; preferably the size of the tumor does not increase by more than 2% from a sample of a subject.
  • the terms“prevent,”“preventing” and“prevention” in the context of the administration of a therapy to a subject refer to the inhibition of the onset or recurrence of a disease or disorder in a subject.
  • the terms“manage,”“managing,” and“management,” in the context of the administration of a therapy to a subject, refer to the beneficial effects that a subject derives from a therapy, which does not result in a cure of a disease or disorder.
  • a subject is administered one or more therapies to“manage” a disease or disorder so as to prevent the progression or worsening of symptoms associated with a disease or disorder.
  • any of the nucleic acids disclosed herein can encode variants of any of the polypeptides disclosed herein.
  • “Variant” used herein with respect to a nucleic acid means (i) a portion or fragment of a referenced nucleotide sequence; (ri) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto.
  • Variant with respect to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity, such as the biological activity of the one or combination of cytokines presented herein.
  • Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity.
  • a conservative substitution of an amino acid i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. Mol. Biol. 157: 105-132 (1982).
  • the hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ⁇ 2 are substituted.
  • the hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity.
  • U.S. Patent No. 4,554,101 incorporated fully herein by reference.
  • Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions may be performed with amino acids having hydrophilicity values within ⁇ 2 of each other. Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.
  • Nucleic acid molecules or nucleic acid sequences of the disclosure include those coding sequences comprising one or more of: nucleic acid sequences encoding any of the amino acid sequences disclosed herein, such as those identified in Table 1, and functional fragments thereof that possess no less than about 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with the coding sequences of the amino acid sequences disclosed herein.
  • Vector used herein means, in respect to a nucleic acid sequence, a nucleic acid sequence comprising a regulatory nucleic acid sequence that controls the replication or expression of an expressible gene.
  • a vector may be either a self-replicating, extrachromosomal vector or a vector which integrates into a host genome. Alternatively, a vector may also be a vehicle comprising the aforementioned nucleic acid sequence.
  • a vector may be a plasmid, bacteriophage, viral particle (isolated, attenuated, recombinant, etc.).
  • a vector may comprise a double-stranded or single-stranded DNA, RNA, or hybrid DNA/RNA sequence comprising double-stranded and/or single-stranded nucleotides.
  • the vector is a viral vector that comprises a nucleic acid sequence that is a viral packaging sequence responsible for packaging one or plurality of nucleic acid sequence that encode one or a plurality of
  • the vector comprises a viral particle comprising a nucleic acid sequence operably linked to a regulator ⁇ ' sequence, wherein the nucleic acid sequence encodes a fusion protein comprising one or a plurality of structural viral polypeptides or fragments thereof.
  • the disclosure relates to any vector composing one or a plurality of nucleic acid sequences encoding any two of the disclosed cytokines of Table 1, and/or any functional fragment or variant thereof comprising at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9.
  • the disclosure relates to the vectors comprising, consisting of, or consisting essentially of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10.
  • the disclosure relates to the vectors comprising a nucleic acid that encodes SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9, or a functional fragment thereof.
  • the disclosure relates to the vectors comprising variants or functional fragments of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10.
  • the disclosure relates to the vectors comprising variants or functional fragments of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10 that comprises at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10.
  • the functional fragment is a subunit of the cytokine known to have biological effect without association with another subunit.
  • “Viral vector” as disclosed herein means, in respect to a vehicle, any virus, virus-like particle, virion, viral particle, or pseudotyped virus that comprises a nucleic acid sequence that directs packaging of a nucleic acid sequence in the virus, vims-like particle, virion, viral particle, or pseudotyped vims.
  • the virus, vims-like particle, virion, viral particle, or pseudotyped vims is capable of transferring a vector (such as a nucleic acid vector) into and/or between host cells.
  • the vims, virus-like particle, virion, viral particle, or pseudotyped virus is capable of transferring a vector (such as a nucleic acid vector) into and/or between target cells, such as a endothelial cell or hematopoietic cell in culture.
  • a vector such as a nucleic acid vector
  • the word“comprise” and variations of the word, such as“comprising” and“comprises,” means“including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps.
  • each step comprises what is listed (unless that step includes a limiting term such as“consisting of’), meaning that each step is not intended to exclude, for example, other additives, components, integers or steps that are not listed in the step.
  • T cell compositions for the treatment of disorders can be administered as a single composition comprising T cell subpopulations stimulated by the methods disclosed herein.
  • the T cell compositions are stimulated with a combination of cytokines disclosed herein for a time period sufficient to stimulate growth and proliferation of the one or plurality of CD4+ and/or CD8+ T cells.
  • the T cell compositions are stimulated with a combination of cytokines disclosed herein and are exposed to one or more tumor-associated antigens or viral antigens for a time period sufficient to stimulate growth and proliferation of the one or plurality of CD4+ and/or CD8+ T cells that are specific to the tumor-associated antigens or viral antigens used for stimulation.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is from about 1 day to about 12 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is from about 2 to about 10 days.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is from about 3 to about 7 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is from about 4 to about 8 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is from about 5 to about 7 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 1 day.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 2 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 3 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or pluralit of CD4+ and/or CD8+ T cells is about 4 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 5 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 6 days.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 7 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 8 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 9 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 10 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 11 days. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is about 12 days.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 5% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 6% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 7% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 8% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 9% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 10% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 11% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 12% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 13% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 14% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 15% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 16% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 17% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 18% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 19% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 20% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 21% of CD8+ or CD4+ T cells produce either IFNy or TNFa. In some embodiments, the time period sufficient to stimulate growth or proliferation of the one or plurality of CD4+ and/or CD8+ T cells is a time period in which no less than about 22% of CD8+ or CD4+ T cells produce either IFNy or TNFa.
  • the subpopulations of T cells are derived through the ex vivo expansion of a single population of T cells, wherein the single population of T cells are exposed to a pool of one or more antigenic peptides (epitopes) of each of the viral antigens in the presence of a combination of two or more cytokines chosen from: IL-18, IL-15, IL-6, IL-7 and IL-4.
  • the combination of cytokines is IL-15 and IL-6.
  • the combination of cytokines is IL-7 and IL-4.
  • the disclosure relates to T cell compositions comprising memory effector T cells that are antigen-specific for one or more viral antigens.
  • the T cell compositions are activated to recognize one or a plurality of viral antigen peptides provided in Figures 8 or peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequences depicted in Figures 8.
  • the T cell compositions are activated to recognize one or more viral antigens of a vims of the family Coromviridae.
  • the T cell compositions are activated to recognize one or more viral antigens of a coronavirus.
  • the T cell compositions are activated to recognize one or more viral antigens of SARS-CoV-2.
  • Coronaviruses are a group of viruses that cause diseases in mammals and birds.
  • Coronaviruses were first discovered in the 1960s. The earliest vims from the family of Coromviridae discovered were infectious bronchitis virus in chickens and two viruses from the nasal cavities of human patients with the common cold that were subsequently named human coronavirus 229E (HCoV-229E) and human coronavirus OC43 (HCoV-OC43). Other members of this family have since been identified, including SARS-CoV in 2003, HCoV NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012, and SARS-CoV-2 (formerly known as 2019-nCoV or novel coronavirus 2019, which caused the global COVID-19 pandemic). Most of these have involved serious respiratory tract infections.
  • SARS-CoV-2 is the virus strain that causes the coronavirus disease 2019 (COVID-19) pandemic, which infected millions of people and caused hundrens of thousand of death worldwide.
  • SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins.
  • the N protein holds the viral RNA genome, and the S, E, and M proteins together create the viral envelope.
  • the complete genome of SARS-CoV-2 has been sequenced and the sequence is publically available in the GenBank database under the accession No. NC_045512.
  • the spike (S) protein is the protein responsible for allowing the vims to attach to and fuse with the membrane of a host cell and has the amino acid sequence of SEQ ID NO: 11 (GenBank Accession No. QHD43416).
  • the envelope (E) protein of SARS-CoV-2 has the amino acid sequence of SEQ ID NO: 12 (GenBank Accession No. QHD43418).
  • the membrane (M) protein of SARS-CoV-2 has the amino acid sequence of SEQ ID NO: 13 (GenBank Accession No. QHD43419).
  • the nucleocapsid (N) protein of SARS-CoV-2 has the amino acid sequence of SEQ ID NO: 14 (GenBank Accession No. QHD43423).
  • T cell compositions activated to recognize one or more viral antigens of SARS-CoV-2 can be prepared by exposing or pulsing antigen presenting cells or artificial antigen presenting cells with one or more peptides or epitopes from SARS-CoV-2.
  • the peptide segments can be generated by making overlapping peptide fragments of the SARS-CoV-2 antigen, as provided for example in commercially available overlapping peptide libraries or“PepMixTM”
  • the overlapping peptide libraries include peptides that are about 7, 8, 9, 10, 11,
  • the peptides are 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 or more ammo acids in length, for example, and there is overlap of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
  • the SARS-CoV-2 specific T cell compositions are generated using one or more antigenic peptides to SARS-CoV-2, or a modified or heteroclitic peptide derived from a SARS-CoV-2 antigenic peptide.
  • SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides (for example, peptides that are from about 10 to about 20 amino acids in length) from one or a combination of the structural proteins of SARS-CoV-2 disclosed herein, such as 15- mers peptides containing amino acids overlap (for example 11 ammo acids of overlap) between each peptide formed by scanning the proteins having the ammo acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and/or SEQ ID NO: 14, or functional fragments or variants thereof.
  • a SARS-CoV-2 antigen library comprising a pool of peptides (for example, peptides that are from about 10 to about 20 amino acids in length) from one or a combination of the structural proteins of SARS-CoV-2 disclosed herein, such as 15- mers peptides containing amino acids overlap (for example 11 ammo acids of overlap) between each peptide
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 11, or functional fragments or variants thereof. In some embodiments, the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 12, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 13, or functional fragments or variants thereof. In some embodiments, the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 12, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 13, or functional fragments or variants thereof
  • the SARS-CoV- 2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12 and SEQ ID NO: 13, or functional fragments or variants thereof. In some embodiments, the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV- 2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS- CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen librar comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen librar comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12,
  • the T cell compositions can be generated through the ex vivo expansion of a first T cell population exposed to one or more antigenic peptides of each of the selected viral antigens separately, wherein following activation and expansion of lymphocytes, the first T cell population is combined with a second T cell population stimulated by a cytokine composition disclosed herein into a single composition for administration.
  • the T cell compositions can be derived through the ex vivo expansion of a first and second T cell populations exposed to one or more antigenic peptides of each of the selected viral antigens separately, wherein following activation and expansion, the separate T cell populations are each individually administered simultaneously or sequentially to the subject.
  • the first and second T cell populations are derived from the same donor source.
  • the first or second T cell populations are derived from one or more different donor sources.
  • the cells are contacted sequentially or simultaneously with any of the cytokine combinations disclosed herein and one or more polypeptides or nucleic acid sequences encoding polypeptides chosen from one or a combination of peptides that comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequences depicted in Figures 8 or variants or functional fragments thereof.
  • the cells are contacted sequentially or simultaneously with any of the cytokine combinations disclosed herein and one or more peptides (for example, peptides that are from about 10 to about 20 amino acids in length) from one or a combination of SARS-CoV-2 antigens having the amino acid sequences of SEQ ID NO: 11,
  • SEQ ID NO: 12 SEQ ID NO: 13 and/or SEQ ID NO: 14, or functional fragments or variants thereof.
  • the T cell compositions described herein may be derived from a population of cells from an autologous source, an allogeneic source, for example a healthy donor not suffering from a disorder, or cord blood.
  • the T cells compositions described herein may be derived from a population of cells from a subject diagnosed with or suspected of having a viral infection.
  • the T cells compositions described herein may be derived from a population of cells from a subject diagnosed with or suspected of having coronaviral infection.
  • the T cells compositions described herein may be derived from a population of cells from a subject diagnosed with or suspected of having infection of SARS-CoV-2.
  • the T cells compositions described herein may be derived from a population of cells from a subject diagnosed with or suspected of having COVID-19.
  • Non-limiting exemplar ⁇ ' methods of generating ex vivo primed and expanded T cells capable of recognizing at least one antigenic peptide of a tumor antigen can be found in Shafer et al, Leuk Lymphoma (2010) 51(5):870-880; Cruz et al., Clm Cancer Res., (2011) 17(22): 7058-7066; Quintarelli et al., Blood (2011) 117(12): 3353-3362; Chapuis et al., Sci Transl Med (2013) 5(174): 174ra27; and US 2017/0037369, all incorporated herein by reference in their entireties.
  • one or more antigenic peptides (epitopes) from the target viral antigen is used in addition to the cytokine compositions disclosed herein.
  • a single antigenic peptide, multiple antigenic peptides, or a library of antigenic peptides can be used to prime and activate a T cell subpopulation targeting each of the specific viral antigens.
  • the peptide segments can be generated by making overlapping peptide fragments of viral antigen that are from about 5 to about 15 amino acids in length as discussed above.
  • generation of the T cell composition can be accomplished through the ex vivo priming and activation of the T cell subpopulations with selected antigenic epitopes of the targeted viral antigen, for example, a single epitope or multiple specific epitopes of the viral antigen.
  • the T cell subpopulation is activated and primed with pooled peptides to a viral antigen, wherein the pooled peptides include a library of overlapping peptides from the viral antigen (peptide mix) which has been enriched by additionally including one or more specific known, identified, or heteroclitic epitopes of the viral antigen.
  • the peptides used to prime the T cells are the same length.
  • the peptides are of varying lengths. In other embodiments, the peptides included in the pool for priming the T cells substantially only include know n viral antigenic epitopes. In some embodiments, the T cell subpopulation is primed with one or more antigenic peptides expressed by a patient’s tumor. In some embodiments, the T cell subpopulation is primed with one or more neoantigens. In some embodiments, the neoantigen is a mutated form of an endogenous protein derived through a single point mutation, a deletion, an insertion, a frameshift mutation, a fusion, mis-spliced peptide, or intron translation of the targeted tumor cells comprising the viral antigens.
  • the T cell composition is derived through the ex vivo expansion of separate T cell populations (a first T cell population and a second T cell population), wherein the T cell composition includes T cell subpopulations primed separately to a pool of viral peptides, wherein each T cell subpopulation is specific for a single viral antigenic peptide.
  • the pooled viral peptides are comprised of overlapping peptides derived from viral peptides selected from those provided in FIG. 9.
  • the pooled viral peptides are comprised of overlapping peptides denved from viral peptides chosen from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14.
  • the pooled viral peptides are comprised of overlapping peptides derived from the viral antigen of SEQ ID NO: 11, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 11.
  • the pooled viral peptides are comprised of overlapping peptides derived from the viral antigen of SEQ ID NO: 12, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 12.
  • the pooled viral peptides are comprised of overlapping peptides derived from the viral antigen of SEQ ID NO: 13, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 13.
  • the pooled viral peptides are comprised of overlapping peptides derived from the viral antigen of SEQ ID NO: 14, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 14.
  • the pooled viral peptides derived from the viral antigen of SEQ ID NO: 11, or functional fragments or variants thereof are further enriched with one or more additional peptides derived from SEQ ID NO: 12, SEQ ID NO: 13 and/or SEQ ID NO: 14, or functional fragments or variants thereof.
  • the pooled viral peptides derived from the viral antigen of SEQ ID NO: 12, or functional fragments or variants thereof are further ennched with one or more additional peptides derived from SEQ ID NO: 11, SEQ ID NO: 13 and/or SEQ ID NO: 14, or functional fragments or variants thereof.
  • the pooled viral peptides derived from the viral antigen of SEQ ID NO: 13, or functional fragments or variants thereof are further enriched with one or more additional peptides derived from SEQ ID NO: 11, SEQ ID NO: 12 and/or SEQ ID NO: 14, or functional fragments or variants thereof.
  • the pooled viral peptides derived from the viral antigen of SEQ ID NO: 14, or functional fragments or variants thereof are further enriched with one or more additional peptides derived from SEQ ID NO: 11, SEQ ID NO: 12 and/or SEQ ID NO: 13, or functional fragments or variants thereof.
  • the T cell composition is derived through the ex vivo expansion of separate T cell populations, wherein the T cell composition includes separate T cell subpopulations primed to a pool of peptides comprising one or more antigenic peptides or epitopes thereof selected from PRAME, Survivin, and WT1.
  • the pooled peptides are comprised of overlapping peptides derived from antigens selected from PRAME, Survivin, and WT1, or combinations thereof.
  • the pooled viral antigens are further enriched with one or more additional peptides selected from PRAME, Survivin, and WT1 having the following sequence, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto.
  • the epitopes are one or a combination from Table 2:
  • the epitopes are one or a combination from Table 3:
  • the epitopes are one or a combination from Table 4:
  • the pooled peptides include one or more peptides selected from SEQ ID NO: 15 (PRAME), one or more peptides selected from SEQ ID NO: 16 (Survivin), and one or more peptides selected from SEQ ID NO: 17 (WT1), or combinations thereof.
  • PRAME one or more peptides selected from SEQ ID NO: 15
  • SEQ ID NO: 16 Survivin
  • WT1 peptides selected from SEQ ID NO: 17
  • the ratio of the T cell subpopulations that comprise the T cell composition is correlated with the tumor expression profile of the subject.
  • compositions of cytokines comprise functional fragments thereof or variants of the disclosed cytokines of Table 1 that comprise at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identify to the amino acids disclosed in Table 1.
  • IL-15 The amino acid sequence of the immature/precursor form of native human IL-15, which comprises the long signal peptide (underlined) and the mature human native IL-15 (italicized), is provided:
  • nucleotide sequence encoding the immature/precursor form of native human IL-15 which comprises the nucleotide sequence encoding the long signal peptide (underlined) and the nucleotide sequence encoding the mature human native IL-15 (italicized), is provided:
  • the nucleic acid is an isolated or purified nucleic acid.
  • the nucleic acids encode the immature or precursor form of a naturally occurring mammalian IL-15, IL-7, IL-6, IL-4 or IL-18.
  • the nucleic acids encode the mature form of a naturally occurring mammalian IL-15, IL-7, IL-6, IL-4 or IL-18 free of signal peptide.
  • the nucleic acids encoding native IL-15, IL-7, IL-6, IL-4 or IL-18 encode the precursor form of naturally occurring human IL-15, IL-7, IL-6, IL-4 or IL- 18.
  • the nucleic acids encoding native IL-15, IL-7, IL-6, IL-4 or IL-18 encode the mature form of naturally occurring human IL-15, IL-7, IL-6, IL-4 or IL-18.
  • the nucleic acids encoding IL-15, IL-7, IL-6, IL-4 or IL-18 comprise at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the nucleotide sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10, or functional fragments or vanants thereof.
  • the nucleic acids encoding IL-15, IL-7, IL-6, IL-4 or IL-18 comprise the nucleotide sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10, or functional fragments or variants thereof.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the immature or precursor form of a naturally occurring mammalian IL-15, or functional fragments or variants thereof. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the mature form of a naturally occurring mammalian IL-15, or functional fragments or variants thereof. In some embodiments, the naturally occurring mammalian IL-15 is a human IL-15. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-15 comprising at least about 70%, 75%, 80%, 85%, 90%, 91%,
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-15 comprising the amino acid sequence of SEQ ID NO: 1, or functional fragments or variants thereof.
  • the terms“IL-15 variant,”“interleukin- 15 variant,” or“functional fragment” or“variant” of IL-15 in the context of proteins or polypeptides, refer to: (a) a polypeptide that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a native mammalian IL-15 polypeptide, such as the IL-15 polypeptide of SEQ ID NO: 1; (b) a polypeptide encoded by a nucleic acid sequence that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a nucleic acid sequence encoding a native mammalian IL-15 polypeptide, such as the IL-15 coding nucleic acid of SEQ ID NO: 2; (c) a polypeptide that contains 1, 2, 3, 4, 5, 6,
  • IL-15 variants also include a polypeptide that comprises the amino acid sequence of a naturally occurring mature form of a mammalian IL-15 polypeptide and a heterologous signal peptide amino acid sequence.
  • an IL-15 variant is a derivative of a native human IL-15 polypeptide, such as the IL-15 polypeptide of SEQ ID NO: 1.
  • an IL-15 variant is a derivative of an immature or precursor form of naturally occurring human IL-15 polypeptide, such as the IL-15 polypeptide of SEQ ID NO: 1.
  • an IL-15 variant is a derivative of a mature form of naturally occurring human IL-15 polypeptide, such as the IL-15 polypeptide of SEQ ID NO: 1 without the signal peptide.
  • an IL- 15 variant is isolated or purified.
  • IL-15 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-15 polypeptide to bind IL-15Ra polypeptide, as measured by assays well known in the art, e.g., ELISA, Biacore, co-immunoprecipitation.
  • IL-15 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-15 polypeptide to induce IL-15-mediated signal transduction, as measured by assays well-known in the art, e.g., electromobility shift assays, ELIS As and other immunoassays.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the immature or precursor form of a naturally occurring mammalian IL-7, or functional fragments or variants thereof. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the mature form of a naturally occurring mammalian IL-7, or functional fragments or variants thereof. In some embodiments, the naturally occurring mammalian IL-7 is a human IL-7.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-7 comprising at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 3, or functional fragments or variants thereof.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-7 comprising the amino acid sequence of SEQ ID NO: 3, or functional fragments or variants thereof.
  • the terms“IL-7 variant,”“interleukin-7 variant,” or“functional fragment” or“variant” of IL-7 in the context of proteins or polypeptides, refer to: (a) a polypeptide that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a native mammalian IL-7 polypeptide, such as the IL-7 polypeptide of SEQ ID NO: 3; (b) a polypeptide encoded by a nucleic acid sequence that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a nucleic acid sequence encoding a native mammalian IL-7 polypeptide, such as the IL-7 coding nucleic acid of SEQ ID NO: 4; (c) a polypeptide that contains 1, 2, 3, 4, 5, 6, 7,
  • IL-7 variants also include a polypeptide that comprises the amino acid sequence of a naturally occurring mature form of a mammalian IL-7 polypeptide and a heterologous signal peptide amino acid sequence.
  • an IL-7 variant is a derivative of a native human IL-7 polypeptide, such as the IL-7 polypeptide of SEQ ID NO: 3.
  • an IL-7 variant is a derivative of an immature or precursor form of naturally occu ing human IL-7 polypeptide, such as the IL-7 polypeptide of SEQ ID NO: 3.
  • an IL-7 variant is a derivative of a mature form of naturally occurring human IL-7 polypeptide, such as the IL-7 polypeptide of SEQ ID NO: 3 without the signal peptide.
  • an IL-7 variant is isolated or purified.
  • IL-7 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-7 polypeptide to bind IL-7R polypeptide, as measured by assays well known in the art, e.g., ELISA, Biacore, co-immunoprecipitation.
  • IL-7 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-7 polypeptide to induce IL-7-mediated signal transduction, as measured by assays well-known in the art, e.g., electromobility shift assays, ELIS As and other immunoassays
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the immature or precursor form of a naturally occurring mammalian IL-6, or functional fragments or variants thereof. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the mature form of a naturally occurring mammalian IL-6, or functional fragments or variants thereof. In some embodiments, the naturally occurring mammalian IL-6 is a human IL-6.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-6 comprising at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 5, or functional fragments or variants thereof.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-6 comprising the amino acid sequence of SEQ ID NO: 5, or functional fragments or variants thereof.
  • the terms“IL-6 variant,”“interleukin-6 variant,” or“functional fragment” or“variant” of IL-6 in the context of proteins or polypeptides, refer to: (a) a polypeptide that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a native mammalian IL-6 polypeptide, such as the IL-6 polypeptide of SEQ ID NO: 5; (b) a polypeptide encoded by a nucleic acid sequence that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a nucleic acid sequence encoding a native mammalian IL-6 polypeptide, such as the IL-6 coding nucleic acid of SEQ ID NO: 6; (c) a polypeptide that contains 1, 2, 3, 4, 5, 6, 7,
  • IL-6 variants also include a polypeptide that comprises the amino acid sequence of a naturally occurring mature form of a mammalian IL-6 polypeptide and a heterologous signal peptide amino acid sequence.
  • an IL-6 variant is a derivative of a native human IL-6 polypeptide, such as the IL-6 polypeptide of SEQ ID NO: 5.
  • an IL-6 variant is a derivative of an immature or precursor form of naturally occurring human IL-6 polypeptide, such as the IL-6 polypeptide of SEQ ID NO: 5.
  • an IL-6 variant is a derivative of a mature form of naturally occurring human IL-6 polypeptide, such as the IL-6 polypeptide of SEQ ID NO: 5 without the signal peptide.
  • an IL-6 variant is isolated or purified.
  • IL-6 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-6 polypeptide to bind IL-6R polypeptide, as measured by assays well known in the art, e.g., ELISA, Biacore, co-immunoprecipitation.
  • IL-15 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-6 polypeptide to induce IL-6-mediated signal transduction, as measured by assays well-known in the art, e.g., electromobility shift assays, ELIS As and other immunoassays.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the immature or precursor form of a naturally occurring mammalian IL-4, or functional fragments or variants thereof. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the mature form of a naturally occurring mammalian IL-4, or functional fragments or variants thereof. In some embodiments, the naturally occurring mammalian IL-4 is a human IL-4.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-4 comprising at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 7, or functional fragments or variants thereof.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-4 comprising the amino acid sequence of SEQ ID NO: 7, or functional fragments or variants thereof.
  • the terms“IL-4 variant,”“interleukin-4 variant,” or“functional fragment” or“variant” of IL-4 in the context of proteins or polypeptides, refer to: (a) a polypeptide that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a native mammalian IL-4 polypeptide, such as the IL-4 polypeptide of SEQ ID NO: 7; (b) a polypeptide encoded by a nucleic acid sequence that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a nucleic acid sequence encoding a native mammalian IL-4 polypeptide, such as the IL-4 coding nucleic acid of SEQ ID NO: 8; (c) a polypeptide that contains 1, 2, 3, 4, 5, 6, 7,
  • IL-4 variants also include a polypeptide that comprises the amino acid sequence of a naturally occurring mature form of a mammalian IL-4 polypeptide and a heterologous signal peptide amino acid sequence.
  • an IL-4 variant is a derivative of a native human IL-4 polypeptide, such as the IL-4 polypeptide of SEQ ID NO: 7.
  • an IL-4 variant is a derivative of an immature or precursor form of naturally occurring human IL-4 polypeptide, such as the IL-4 polypeptide of SEQ ID NO: 7.
  • an IL-4 variant is a derivative of a mature form of naturally occurring human IL-4 polypeptide, such as the IL-4 polypeptide of SEQ ID NO: 7 without the signal peptide.
  • an IL-4 variant is isolated or purified.
  • IL-4 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-4 polypeptide to bind IL-4R polypeptide, as measured by assays well known in the art, e.g., ELISA, Biacore, co-immunoprecipitation.
  • IL-4 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-4 polypeptide to induce IL-4-mediated signal transduction, as measured by assays well-known in the art, e.g., electromobility shift assays, ELIS As and other immunoassays.
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the immature or precursor form of a naturally occurring mammalian IL-18, or functional fragments or variants thereof. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising the mature form of a naturally occurring mammalian IL-18, or functional fragments or variants thereof. In some embodiments, the naturally occurring mammalian IL-18 is a human IL-18. In some embodiments, the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-18 comprising at least about 70%, 75%, 80%, 85%, 90%, 91%,
  • the methods of the disclosure comprise exposing cells to a composition of cytokines comprising an IL-18 comprising the amino acid sequence of SEQ ID NO: 9, or functional fragments or variants thereof.
  • the terms“IL-18 variant,”“interleukin- 18 variant,” or“functional fragment” or“variant” of IL-18 in the context of proteins or polypeptides, refer to: (a) a polypeptide that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a native mammalian IL-18 polypeptide, such as the IL-18 polypeptide of SEQ ID NO: 9; (b) a polypeptide encoded by a nucleic acid sequence that has at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to a nucleic acid sequence encoding a native mammalian IL-18 polypeptide, such as the IL-18 coding nucleic acid of SEQ ID NO: 10; (c) a polypeptide that contains 1, 2, 3, 4, 5, 6,
  • IL-18 variants also include a polypeptide that comprises the amino acid sequence of a naturally occurring mature form of a mammalian IL-18 polypeptide and a heterologous signal peptide amino acid sequence.
  • an IL-18 variant is a derivative of a native human IL-18 polypeptide, such as the IL-18 polypeptide of SEQ ID NO: 9.
  • an IL-18 variant is a derivative of an immature or precursor form of naturally occurring human IL- 18 polypeptide, such as the IL-18 polypeptide of SEQ ID NO: 9.
  • an IL- 18 variant is a derivative of a mature form of naturally occurring human IL-18 polypeptide, such as the IL-18 polypeptide of SEQ ID NO: 9 without the signal peptide.
  • an IL-18 variant is isolated or purified.
  • IL-18 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-18 polypeptide to bind IL-18R polypeptide, as measured by assays well known in the art, e.g., ELISA, Biacore, co-immunoprecipitation.
  • IL-18 variants retain at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% of the function of a native mammalian IL-18 polypeptide to induce IL-18-mediated signal transduction, as measured by assays well-known in the art, e.g., electromobility shift assays, ELIS As and other immunoassays.
  • the disclosure relates to a method of expanding CD8+ and/or CD4+ lymphocytes in an vitro culture comprising contacting the lymphocytes with at least two polypeptides, one or a plurality of nucleic acids encoding at least two polypeptides; or a combination of a nucleic acid and a polypeptide; wherein the at least two polypeptides are cytokines chosen from: IL-15, IL-6, IL-7, IL-4, IL-18 and/or functional fragments or variants thereof.
  • the method relates to contacting one or a plurality of lymphocytes in an in vitro culture with at least one combination of cytokines chosen from a combination of: (i) IL-15 and IL-6, or functional fragments or variants thereof; (ii) IL-7 and IL-4, or functional fragments or variants thereof; and/or (iii) IL-15 and IL-18, or functional fragments or variants thereof.
  • cytokines chosen from a combination of: (i) IL-15 and IL-6, or functional fragments or variants thereof; (ii) IL-7 and IL-4, or functional fragments or variants thereof; and/or (iii) IL-15 and IL-18, or functional fragments or variants thereof.
  • Any combination of cytokines in nucleic acid form or protein form may be exposed to one or more cells.
  • plasmids that stably or transiently express the cytokine or functional fragment or variant thereof may be used.
  • the cell is a hematopoietic stem cell or a hematopoietic progenitor cell.
  • the methods disclosed herein comprise a multistep process of differentiating a naive T cell into a memory effector T cell that is either CD4+ or CD8+ and then, subsequently or simultaneously or prior to differentiating the naive T cells, stimulating the naive T cells with one or a plurality of antigens, such as viral antigens.
  • the method of differentiating the endothelial cells disclosed herein comprises exposing the naive cells to at least one cytokine composition, such as but not limited to one comprising IL-15, at a concentration and for a time period sufficient to cause growth and proliferation of CD8 and a change in character from a naive cell to a memory effector cell.
  • the method of differentiating the endothelial cells disclosed herein comprises exposing the naive cells to at least one cytokine composition, such as but not limited to one comprising IL-6, at a concentration and for a time period sufficient to cause growth and proliferation of CD8 and a change in character from a naive cell to a memory effector cell.
  • the method of differentiating the endothelial cells disclosed herein comprises exposing the naive cells to at least one cytokine composition, such as but not limited to one comprising IL-18, at a concentration and for a time period sufficient to cause growth and proliferation of CD8 and a change in character from a naive cell to a memory effector cell.
  • the method of differentiating the endothelial cells disclosed herein comprises exposing the naive cells to at least one cytokine composition, such as but not limited to one comprising IL-4, at a concentration and for a time period sufficient to cause growth and proliferation of CD4 and a change in character from a naive cell to a memory effector cell.
  • the method of differentiating the endothelial cells disclosed herein comprises exposing the naive cells to at least one cytokine composition, such as but not limited to one comprising IL-7, at a concentration and for a time period sufficient to cause growth and proliferation of CD4 and a change in character from a naive cell to a memory effector cell.
  • at least one cytokine composition such as but not limited to one comprising IL-7
  • the naive T cell is exposed to one or a combination of any of the cytokines listed in Table 1, at a concentration and for a time period sufficient to induce expression of CCR7 and CD45RO.
  • the composition comprising lymphocytes is exposed to one or a combination of any of the cytokines listed in Table 1, optionally after exposure to the one or combination of tumor or viral antigens, at a concentration and for a time period sufficient to alter the change a population of lymphocytes cell to T cell effector memory cells.
  • the disclosure relates to methods by which T cells can be differentiated into memory T cells.
  • Reprogramming of the T cells may be accomplished by exposing the isolated naive T cells to a composition comprising one or a plurality of cytokines disclosed herein for a time sufficient to sequentially activate or induce expression of CCR7 and CD45RO.
  • these cells can also be exposed to tumor antigens for priming and eventual introduction or administration into mammals having cancer comprising the tumor antigens.
  • These cells can also be exposed to viral antigens for priming and eventually introduction or administration into mammals having viral infection by the virus from which the viral antigens are used for priming.
  • CCR7 C-C motif chemokine receptor 7
  • This receptor was identified as a gene induced by the Epstein-Barr virus (EBV), and is thought to be a mediator of EBV effects on B lymphocytes. This receptor is expressed in various lymphoid tissues and activates B and T lymphocytes. It has been shown to control the migration of memory T cells to inflamed tissues, as well as stimulate dendritic cell maturation.
  • the chemokine (C-C motif) ligand 19 (CCL19/ECL) has been reported to be a specific ligand of this receptor.
  • CCR7 from Homo sapiens has the following sequence (GenBank Accession No. AAT52232):
  • Protein tyrosine phosphatase, receptor type, C also known as PTPRC is an enzyme that, in humans, is encoded by the PTPRC gene.
  • PTPRC is also known as CD45 antigen (CD stands for cluster of differentiation), which was originally called leukocyte common antigen (LC A).
  • the CD45 protein family consists of multiple members that are all products of a single complex gene.
  • CD45RO the shortest CD45 isoform, which lacks all three of the A, B, and C regions. This shortest isoform facilitates T cell activation.
  • Receptor-type tyrosine-protein phosphatase C isoform 5 precursor from Homo sapiens has the following sequence (GenBank Accession No. NP_001254727):
  • reprogramming of the T cells according to the present disclosure may be accomplished by exposing the isolated naive T cells to a composition comprising one or a plurality of cytokines disclosed herein for a time sufficient to sequentially activate or induce expression of CCR7 comprising at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 48 and CD45RO comprising at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 49.
  • the disclosure relates to a method of expanding viral antigen specific CD8+ and/or CD4+ T cells in an in vitro culture comprising contacting the antigen presenting cells, such as lymphocytes, with one or a plurality of viral antigens in the presence of one or a plurality of cytokines chosen from: IL-15, IL-6, IL-7, IL-4, IL-18 and/or functional fragments or variants thereof.
  • the antigen presenting cells such as lymphocytes
  • cytokines chosen from: IL-15, IL-6, IL-7, IL-4, IL-18 and/or functional fragments or variants thereof.
  • At least two cytokines are present in the in vitro culture chosen from a combination of: (i) IL-15 and IL-6, or functional fragments or variants thereof; (ii) IL-7 and IL-4, or functional fragments or variants thereof; and/or (lii) IL-15 and IL-18, or functional fragments or variants thereof. Any combination of cytokines in nucleic acid form or protein form may be exposed to one or more cells.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells comprise at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequences depicted in Figures 8.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells are chosen from the viral antigen peptides provided in Figures 8.
  • the disclosure relates to a method of expanding viral antigen specific CD8+ and/or CD4+ T cells in an in vitro culture comprising contacting the antigen presenting cells, such as lymphocytes, with one or a plurality of viral antigens of a virus of the family Coronaviridae in the presence of one or a plurality of cytokines chosen from: IL-15, IL- 6, IL-7, IL-4, IL-18 and/or functional fragments or variants thereof.
  • At least two cytokines are present in the in vitro culture chosen from a combination of: (i) IL-15 and IL-6, or functional fragments or variants thereof; (ii) IL-7 and IL-4, or functional fragments or variants thereof; and/or (iii) IL-15 and IL-18, or functional fragments or variants thereof.
  • any combination of cytokines in nucleic acid form or protein form may be exposed to one or more cells.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells are from a coronavirus.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells are from SARS-CoV-2.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells are peptide fragments of the SARS-CoV-2 antigens comprising the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and/or SEQ ID NO: 14, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and/or SEQ ID NO: 14.
  • the one or plurality of viral antigens used in the methods of the disclosure for priming the cells are in form of a SARS-CoV-2 antigen librar comprising a pool of peptides (for example, peptides that are from about 10 to about 20 amino acids in length) from one or a combination of the structural proteins of SARS-CoV-2 disclosed herein, such as 15-mers peptides containing amino acids overlap (for example 11 amino acids of overlap) between each peptide formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12,
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 11, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 12, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity SEQ ID NO: 12.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV- 2 antigen library comprising a pool of peptides formed by scanning the protein having the amino acid sequence of SEQ ID NO: 13, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity SEQ ID NO: 13.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the protein having the ammo acid sequence of SEQ ID NO: 14, or functional fragments or variants thereof having at least about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 12, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 13, or functional fragments or variants thereof
  • the SARS-CoV- 2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12 and SEQ ID NO: 13, or functional fragments or variants thereof. In some embodiments, the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV- 2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS- CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen library comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14, or functional fragments or variants thereof.
  • the SARS-CoV-2 specific T cell compositions are generated using a SARS-CoV-2 antigen librar comprising a pool of peptides formed by scanning the proteins having the amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12,
  • the disclosure relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of T cells that specifically bind to a Coronaviridae peptide having at least about a 80%, 85%, 90%, 95% sequence identity to SEQ ID NO:l 1, SEQ ID NO: 12, SEQ ID NO: 13 and/or SEQ ID NO: 14.
  • the naive T cells in the pharmaceutical compositions may be derived by a biopsy of a donor (optionally frozen after differentiation and harvesting) followed by expansion in culture using the steps disclosed herein.
  • Blood, serum or lymph tissue may be biopsied from a subject.
  • the starting material is composed of three gm punch biopsies collected using standard aseptic practices. Blood may be collected by the treating physician, placed into a vial.
  • the biopsies are shipped at a temperature of about 2 to about 8°C refrigerated shipper back to the manufacturing facility. After arnval at the manufacturing facility, the biopsy is inspected and, upon acceptance, transferred directly to the manufacturing area.
  • preparation of the engineered cells includes one or more culture and/or preparation steps.
  • the cells for introduction of the composition comprising the one or more cytokines may be isolated from a sample, such as a biological sample, e.g., one obtained from or derived from a subject.
  • the subject from which the cell is isolated is one having the disease or condition or in need of a cell therapy or to which cell therapy will be administered.
  • the subject in some embodiments is a human in need of a particular therapeutic intervention, such as the adoptive cell therapy for which cells are being isolated, processed, and/or engineered.
  • the cells in some embodiments are primary cells, e g., primary human cells.
  • the samples include tissue, fluid, and other samples taken directly from the subject, as well as samples resulting from one or more processing steps, such as separation, centrifugation, genetic engineering (e.g. transduction with viral vector), washing, and/or incubation.
  • the biological sample can be a sample obtained directly from a biological source or a sample that is processed.
  • Biological samples include, but are not limited to, body fluids, such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine and sweat, tissue and organ samples, including processed samples derived therefrom.
  • the sample from which the cells are derived or isolated is blood or a blood-derived sample, or is or is derived from an apheresis or leukapheresis product.
  • exemplary samples include whole blood, peripheral blood mononuclear cells (PBMCs), leukocytes, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut associated lymphoid tissue, mucosa associated lymphoid tissue, spleen, other lymphoid tissues, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testes, ovaries, tonsil, or other organ, and/or cells derived therefrom.
  • Samples include, in the context of cell therapy, e.g., adoptive cell therapy, samples from autologous and allogeneic sources.
  • the cells are derived from cell lines, e.g., T cell lines.
  • the cells in some embodiments are obtained from a xenogeneic source, for example, from mouse, rat, non human primate, or pig.
  • isolation of the cells includes one or more preparation and/or non-affmity-based cell separation steps.
  • cells are washed, centrifuged, and/or incubated in the presence of one or more reagents, for example, to remove unwanted components, enrich for desired components, lyse or remove cells sensitive to particular reagents.
  • cells are separated based on one or more property such as density, adherent properties, size, sensitivity and/or resistance to particular components.
  • cells from the circulating blood of a subject are obtained, e.g., by apheresis or leukapheresis.
  • the samples contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and/or platelets, and in some aspects contains cells other than red blood cells and platelets.
  • the blood cells collected from the subject are washed, e.g., to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps.
  • the cells are washed with phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the wash solution lacks calcium and/or magnesium and/or many or all divalent cations.
  • a washing step is accomplished a semi-automated“flow- through” centrifuge (for example, the Cobe 2991 cell processor, Baxter) according to the manufacturer's instructions.
  • a washing step is accomplished by tangential flow filtration (TFF) according to the manufacturer's instructions.
  • the cells are resuspended in a variety of biocompatible buffers after washing, such as, for example,
  • components of a blood cell sample are removed and the cells directly resuspended in culture media.
  • the methods include density -based cell separation methods, such as the preparation of white blood cells from peripheral blood by lysing the red blood cells and centrifugation through a Percoll or Ficoll gradient.
  • the isolation methods include the separation of different cell types based on the expression or presence in the cell of one or more specific molecules, such as surface markers, e.g., surface proteins, intracellular markers, or nucleic acid. In some embodiments, any known method for separation based on such markers may be used. In some embodiments, the separation is affinity- or immunoaffmity-based separation.
  • the isolation in some aspects includes separation of cells and cell populations based on the cells' expression or expression level of one or more markers, typically cell surface markers, for example, by incubation with an antibody or binding partner that specifically binds to such markers, followed generally by washing steps and separation of cells having bound the antibody or binding partner, from those cells having not bound to the antibody or binding partner.
  • Such separation steps can be based on positive selection, in which the cells having bound the reagents are retained for further use, and/or negative selection, in which the cells having not bound to the antibody or binding partner are retained. In some examples, both fractions are retained for further use. In some aspects, negative selection can be particularly useful where no antibody is available that specifically identifies a cell type in a heterogeneous population, such that separation is best carried out based on markers expressed by cells other than the desired population.
  • the separation need not result in 100% enrichment or removal of a particular cell population or cells expressing a particular marker.
  • positive selection of or enrichment for cells of a particular type refers to increasing the number or percentage of such cells, but need not result in a complete absence of cells not expressing the marker.
  • negative selection, removal, or depletion of cells of a particular type refers to decreasing the number or percentage of such cells, but need not result in a complete removal of all such cells.
  • multiple rounds of separation steps are carried out, where the positively or negatively selected fraction from one step is subjected to another separation step, such as a subsequent positive or negative selection.
  • a single separation step can deplete cells expressing multiple markers simultaneously, such as by incubating cells with a plurality of antibodies or binding partners, each specific for a marker targeted for negative selection.
  • multiple cell types can simultaneously be positively selected by incubating cells with a plurality of antibodies or binding partners expressed on the various cell types.
  • specific subpopulations of T cells such as cells positive or expressing one or more markers, e.g., CD4+, CD25+, CD27+, CD4+, CD8+.
  • a sample of PBMCs or other white blood cell sample is subjected to selection of CD4+ cells, where both the negative and positive fractions are retained.
  • the negative fraction then is subjected to negative selection based on expression o, for example, CD14 and CD45RA, and positive selection based on a marker characteristic of central memory T cells, such as CD62L or CCR7, where the positive and negative selections are carried out in either order.
  • CD4+ T helper cells are sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens.
  • CD4+ lymphocytes can be obtained by standard methods.
  • naive CD4+ T lymphocytes are CD45RO+, CD45RA+, CD62L+, CD4+ T cells.
  • central memory CD4+ cells are CD62L+ and CD45RO+.
  • a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CDl lb, CD16, HLA-DR, and CD8.
  • the antibody or binding partner is bound to a solid support or matrix, such as a magnetic bead or paramagnetic bead, to allow for separation of cells for positive and/or negative selection.
  • a solid support or matrix such as a magnetic bead or paramagnetic bead
  • the cells and cell populations are separated or isolated using immunomagnetic (or affinity magnetic) separation techniques (reviewed in Methods in Molecular Medicine, vol. 58: Metastasis Research
  • the sample or composition of cells to be separated is incubated with small, magnetizable or magnetically responsive material, such as magnetically responsive particles or microparticles, such as paramagnetic beads (e.g., such as Dynabeads or MACS beads).
  • the magnetically responsive material, e.g., particle generally is directly or indirectly attached to a binding partner, e.g., an antibody, that specifically binds to a molecule, e.g., surface marker, present on the cell, cells, or population of cells that it is desired to separate, e.g., that it is desired to negatively or positively select.
  • the magnetic particle or bead comprises a magnetically responsive material bound to a specific binding member, such as an antibody or other binding partner.
  • Suitable magnetic particles include those described in Molday, U.S. Pat. No.
  • the preparation methods include steps for freezing, e.g., cry opreserving, the cells, either before or after isolation, incubation, and/or engineering.
  • the freeze and subsequent thaw step removes granulocytes and, to some extent, monocytes in the cell population.
  • the cells are suspended in a freezing solution, e.g., following a washing step to remove plasma and platelets. Any of a variety of known freezing solutions and parameters in some aspects may be used.
  • a freezing solution e.g., following a washing step to remove plasma and platelets.
  • Any of a variety of known freezing solutions and parameters in some aspects may be used.
  • PBS containing 20% DMSO and 8% human serum albumin (HSA), or other suitable cell freezing media. This is then diluted 1 : 1 with media so that the final concentration of DMSO and HSA are 10% and 4%, respectively.
  • the cells are then frozen to -80° C. at a rate of 1° per minute and stored in the vapor phase of a liquid
  • the provided methods include cultivation, incubation, culture, and/or genetic engineering steps.
  • the cell populations are incubated in a culture-initiating composition.
  • the incubation and/or engineering may be carried out in a culture vessel, such as a unit, chamber, well, column, tube, tubing set, valve, vial, culture dish, bag, or other container for culture or cultivating cells.
  • the cells are incubated and/or cultured prior to or in connection with genetic engineering.
  • the incubation steps can include culture, cultivation, stimulation, activation, and/or propagation.
  • the compositions or cells are incubated in the presence of stimulating conditions or a stimulatory agent. Such conditions include those designed to induce proliferation, expansion, activation, and/or survival of cells in the population, to mimic antigen exposure, and/or to prime the cells for genetic engineering, such as for the introduction of a recombinant antigen receptor.
  • the conditions can include one or more of particular media, temperature, oxygen content, carbon dioxide content, time, agents, e.g., nutrients, amino acids, antibiotics, ions,
  • cytokines such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate the cells.
  • the stimulating conditions or agents include one or more agent, e.g., ligand, which is capable of activating an intracellular signaling domain of a TCR complex.
  • agent e.g., ligand
  • the agent turns on or initiates TCR/CD3 intracellular signaling cascade in a T cell.
  • agents can include antibodies, such as those specific for a TCR, e.g. anti-CD3.
  • the stimulating conditions include one or more agent, e.g. ligand, which is capable of stimulating a costimulatory receptor, e.g., anti-CD28.
  • agents and/or ligands may be, bound to solid support such as a bead, and/or one or more cytokines.
  • the expansion method may further compnse the step of adding anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration of at least about 0.5 ng/ml).
  • the isolated cells are part of one or more disclosed compositions of T cells and those T cells are stimulated with a composition of cytokines agents including IL-15 and/or IL-6.
  • the composition of cytokines is free of one or more of: IL-1, IL-12, IL-4, or IL-7.
  • methods of the disclosure relate to stimulating isolated naive T cell compositions with a composition of at least two cytokines (such as IL-6 and IL-15) and are free of one or more of: IL-1, IL-12, IL-4, or IL-7.
  • the methods of expanding, proliferating or stimulating the T cell populations are free of a step of exposing the T cell populations to cytokines one or more of: IL-2, IL-4, IL-4, IL-7, IL-12, IL-18 and IL-27. In some embodiments, the methods disclosed herein are free of a step of using a composition of feeder cells.
  • T cells to be administered can be determined by a physician with consideration of individual differences in age, weight, extent of disease and condition of the subject.
  • T cell therapies are defined by number of cells per kilogram of body weight. However, because T cells will replicate and expand after transfer, the administered cell dose will not resemble the final steady-state number of cells.
  • a pharmaceutical composition comprising the T cells of the present invention may be administered at a dosage of 10 4 to 10 9 cells/kg body weight. In another embodiment, a pharmaceutical composition comprising the T cells of the present invention may be administered at a dosage of 10 5 to 10 6 cells/kg body weight, including all integer values within those ranges.
  • compositions comprising the T cells of the present invention may also be administered multiple times at these dosages.
  • the cells can be administered by using infusion techniques that are known in the art (see, for example, Rosenberg et al., 1988, New England Journal of Medicine, 319: 1676).
  • the optimal dosage and treatment regimen for a particular subject can be readily determined by one skilled in the art by monitoring the patient for signs of disease and adjusting the treatment accordingly.
  • administration of any of the compositions embodied herein, e.g. a T cell, for the treatment of a viral infection can be combined with other cell-based therapies, for example, stem cells, antigen presenting cells, etc.
  • composition of the present invention may be prepared in a manner known in the art and are those suitable for parenteral administration to mammals, particularly humans, comprising a therapeutically effective amount of the composition alone, with one or more pharmaceutically acceptable carriers or diluents.
  • pharmaceutically acceptable carrier as used herein means any suitable carriers, diluents or excipients.
  • compositions of the invention may also include other supplementary physiologically active agents.
  • compositions include those suitable for parenteral administration, including subcutaneous, intramuscular, intraarticular, intravenous and intradermal administration.
  • compositions may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. Such methods include preparing the carrier for association with the compositions comprising a therapeutically effective amount of stimulated T cells. In general, the compositions are prepared by uniformly and intimately bringing into association any active ingredients with liquid carriers.
  • the composition is suitable for parenteral administration. In another embodiment, the composition is suitable for intravenous administration. In another embodiment, the composition is suitable for intraarticular administration.
  • compositions suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bactericides and solutes, which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the invention also contemplates the combination of the T cell composition of the present disclosure with other drugs and/or in addition to other treatment regimens or modalities such as surgery.
  • the composition of the present invention is used in combination with known therapeutic agents the combination may be administered either in sequence (either continuously or broken up by periods of no treatment) or concurrently or as an admixture.
  • the disclosure relates to a system comprising a cell culture unit that is utilized to culture and expand a T cell population described herein.
  • the cell culture unit comprises one or a plurality of cell reactor surfaces housed in at least a first compartment, the one or plurality of cell reactor surfaces in fluid connection with a first and second media line, the first media line in fluid communication with a first media inlet, the second media line in fluid communication to a first media outlet.
  • the one or plurality of cell reactor surfaces are configured in a cylindrical form with a hollow volume fixed within a cylindrical first compartment; wherein the first media line and the second media line are positioned on opposite faces of the cylindrical first compartment.
  • the first media line can be attached to a first sealable aperture configured for sterile attachment of a cell culture media source.
  • the system further comprises a pump and a fluid regulator in operable contact with the first media line, wherein the pump is capable of generating pressure in the first media line and wherein the fluid regulator is capable of regulating the speed of fluid from the pump through the first compartment and into the second media line.
  • the one or plurality of cell reactor surfaces can have a surface area from about 0.5 m 2 to about 100.0 m 2 , including any value therein, such as about 3 m 2 , about 4 m 2 , about 5 m 2 , about 6 m 2 , about 7 m 2 , about 8 m 2 , about 9 m 2 , about 10 m 2 , about 11 m 2 , about 12 m 2 , about 13 m 2 , about 14 m 2 , about 15 m 2 , about 16 m 2 , about 17 m 2 , about 18 m 2 , about 19 m 2 , about 20 m 2 , about 21 m 2 , about 22 m 2 , about 23 m 2 , about 24 m 2 , about 25 m 2 , about 26 m 2 , about 27 m 2 , about 28 m 2 , about 29 m 2 , about 30 m 2 , about 31 m 2 , about 32 m 2 , about 33 m 2
  • the system further comprises a gas transfer module in operable connection to the one or plurality of cell reactor surfaces.
  • the gas module comprises a gas pump and a gas regulator connected to the first compartment by a first gas line.
  • the first compartment comprises at least one gas outlet.
  • the gas pump is capable of generating air pressure from the pump to the first compartment through the first gas line.
  • the gas outlet can be one or more vents or the gas outlet can be configured for sterile connection to one or more vents.
  • the gas regulator is capable of regulating the speed of gas from the pump through the first compartment.
  • Some embodiments further comprise a first gas inlet in operable connection to the gas transfer module.
  • the first gas inlet is attached to a second sealable aperture configured for sterile attachment of a gas source.
  • the gas source can be any known gas storage and/or delivery system, such as for example a container or a tank.
  • the system can further comprise an apheresis unit in fluid communication with the cell culture unit.
  • Suitable apheresis units include the Spectra Optia Apheresis System
  • system further comprises a harvesting compartment in fluid communication with the cell culture unit. Suitable harvesting
  • a cell culture system as described herein can be used to expand memory effector T cells from a subject through culturing one or a plurality of T cells in the system and allowing the T cells to grown in the first compartment for a time period sufficient to proliferate.
  • the T cells can be introduced into the system through the system’s first compartment.
  • the T cells are CD4+ T cells. In some embodiments, the T cells are CD8+ T cells. In some embodiments, the T cells are a mixture of CD4+ and CD8+ T cells. In some embodiments, the T cells are CD45A+ T cells.
  • the disclosure also relates to a system comprising a cell culture unit comprising one or a plurality of cell reactor surfaces housed in a plurality of compartments, each compartment separated by a removable partition first compartment comprising at least one cell reactor surface, at least one cell reactor surface in fluid connection with a first and second media line, the first media line in fluid communication with a first media inlet, the second media line in fluid communication to a first media outlet.
  • the cell culture unit comprises a single cell culture chamber comprising multiple partitions, each partition independently removable and independently in fluid connection with the first and the second media line and each partition or set of partitions defining a distinct compartment.
  • the cell culture unity comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more compartments, each compartment separated by and/or defined by one or more partitions.
  • the compartments are configured in a grid or linear pattern.
  • each partition separating one compartment from another compartment may be removed such that the cell reactor surface of a first compartment is or becomes contiguous with a cell reactor surface of a second compartment. The removal of one or more partitions allows for an increased surface area onto which cells from one compartment (such as the first compartment) may proliferate and/or grow into another compartment (such as the second compartment) during a method of culturing.
  • the cell culture unit comprises a set of side walls defining a single surface area divided among 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more compartments each compartment with at least one or a plurality of cell reactor surfaces. In some embodiments, each compartment has at least a first cell reactor surface.
  • the disclosure relates to a method of growing T cell populations on a tissue culture system disclosed herein, wherein primary sets of lymphocytes are plated at about a concentration of from about 0.001 to about 10 million cells per milliliter into one or more compartments of the cell culture unit and then allowed to grow to a confluent layer on surface area of from about 1 to about 200 squared centimeters.
  • the method further comprises removing one or more partitions to allow the cells to grow in a second compartment until confluence, when again, optionally, another partition may successively be removed to allow for more surface for expanded culture.
  • the method of culturing further comprises repeating the step of removing a partition for each of the compartments into which cells should grow.
  • the cell culture unit comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more partitions each of which corresponding to the physical barrier between a second and third compartment, between a third and fourth compartment, between a fourth and fifth compartment, between a fifth and sixth compartment, between a sixth and seventh compartment, between a seventh and eighth compartment, between an eighth and ninth compartment, between a ninth and tenth
  • one or more of the partitions comprise an interior portion, a frame portion and an exterior portion.
  • the interior portion of the partition is positioned in the closed portion of the system; the frame portion spans a wall of the culture system separating the interior of the culture system to the exterior of the system; and the exterior portion is positioned outside of the system.
  • a seal operably fits around the frame portion of one or more of the partitions such that removal of the partition does not introduce pathogens to and/or does not expose the environment outside of the tissue culture system to the interior of the tissue culture system.
  • the cell density of each compartment is from about 0.1 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 0.1 to about 10 million cells per mL of cell culture media. In some embodiments, the cell densit of each compartment is from about 0.5 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 1.0 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 2 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 3 to about 10 million cells per mL of cell culture media.
  • the cell density of each compartment is from about 4 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density' of each compartment is from about 5 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 6 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 7 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 8 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 9 to about 10 million cells per mL of cell culture media. In some embodiments, the cell density' of each compartment is from about 0.1 to about 20 million cells per mL of cell culture media. In some embodiments, the cell density of each compartment is from about 0.1 to about 50 million cells per mL of cell culture media.
  • the systems disclosed herein comprise a cell density of from about 0.01 million to about 10 million cells per square centimeter. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.03 million to about 5 million cells per square centimeter. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.07 million to about 5 million cells per square centimeter. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.03 million to about 5 million cells per square centimeter. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.001 million to about 5 million cells per square centimeter.
  • the systems disclosed herein comprise a cell density of from about 0.002 million to about 4 million cells per square centimeter. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.003 million to about 5 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.004 million to about 5 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.005 million to about 5 million cells per square centimeter of surface area of cell reactor surface.
  • the systems disclosed herein comprise a cell density of from about 0.006 million to about 5 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.007 million to about 5 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.001 million to about 4 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.001 million to about 3 million cells per square centimeter of surface area of cell reactor surface. In some embodiments, the systems disclosed herein comprise a cell density of from about 0.003 million to about 3 million cells per square centimeter of surface area of cell reactor surface.
  • Example 1 Identification of New Cytokine Combinations for Antigen-specific T cell Therapy Products via a High Throughput Multi-parameter Assay
  • VSTs viral-specific T cells
  • Current manufacturing approaches are rapid but growth conditions can still be further improved.
  • a high-throughput flow cytometry -based assay using 40 cytokine combinations in a 96 well plate was designed to fully characterize T cell viability, function, growth, and differentiation.
  • Peripheral blood mononuclear cells (PBMC) from six consenting donors were seeded at 100,000 cells/well with pools of CMV peptides from IE-1 and pp65, and combinations of IL15, IL6, IL21, IFNa, IL12, IL18, IL4, and IL7.
  • IL15/IL6 and IL4/IL7 were optimal for expansion of viral specific CD3+ T cells, (18-fold and 14-fold respectively compared with unstimulated controls).
  • CD8+ T cells expanded 24-fold in IL15/IL6, and 9-fold in IL4/IL7 cultures (p ⁇ 0.0001).
  • CD4+ T cells expanded 27-fold in IL4/IL7 and 15-fold in IL15/IL6 (p ⁇ 0.0001).
  • CD45RO+ CCR7- effector memory T cells were the preponderant cells (76.8% and 72.3% in IL15/IL6 and IL15/IL7 cultures respectively). Cells cultured in both cytokine conditions were potent, with 19.4% of CD3+ cells cultured in
  • Adoptive T cell immunotherapies are increasingly used to treat infection and malignant disease.
  • a common technique involves culturing T cells with antigen presenting cells (APC) exposed to peptide antigens in the presence of a cytokine cocktail.
  • APC antigen presenting cells
  • cytokine cocktail Several immunomodulatory cytokines are currently used to promote T cell division and differentiation, but optimal conditions for the growth and function of peptide stimulated T cell products have yet to be fully defined.
  • Cell products used in clinical trials have typically supplemented T cell cultures with the growth promoting cytokines IL2, IL15, IL4 and IL7 [1-3]
  • the search to optimize culture conditions is, however, limited by the time and labor needed to screen multiple cytokine combinations.
  • a flow cytometry-based approach was therefore established to rapidly evaluate many cytokine combinations in a single 96 well plate to measure T cell phenotype and potency on a limited numbers of cells.
  • IL4 enhances survival of resting T cells and induces CD4+ Th2 helper differentiation [5-7]
  • IL15 promotes survival and diversity of CD8+ memory T cells [8, 9]
  • IL2 is a canonical T cell growth cytokine which continues to be used in clinical trials due to its effectiveness in expanding T cells derived from tumor infiltrating lymphocytes [10]
  • IL6 may enhance Thl7 development [11]
  • IL7 promotes T cell homeostatic survival [12-14]
  • IL21 promotes the activity of CD8+ T cells [15-17]
  • the manufacturing methods have transitioned from culturing T cells in 24 well plates with IL2 and APC transduced with viral antigens [18-20] to a simplified culture containing a combination of IL4 and IL7 in G-Rex gas permeable devices with soluble mixes of peptides [3, 21, 22]
  • This system rapidly expands functionally competent T cells specific for multiple viruses.
  • T cells are currently characterized for safety, phenotype, and potency in three separate assays: ELISPOT for IFN-g release, 51 Cr release to measure cytotoxicity, and flow cytometry to identify cellular phenotype.
  • ELISPOT for IFN-g release
  • 51 Cr release to measure cytotoxicity
  • flow cytometry to identify cellular phenotype.
  • 13 color flow cytometry panels make it possible to measure intracellular cytokines, surface marker phenotype, and correlates of cytotoxicity and alloreactivity, in a single assay to define product quality.
  • Flow cytometric assays minimize culture volume reducing the number of cells needed for validation, while increasing the number of testable conditions that can be applied to donor PBMC. Using this approach, new cytokine combinations controlling phenotypic diversity, growth and function of viral specific T cells products were identified. It was found that high throughput screening by multicolor flow cytometry is affordable and practical for product development.
  • Peripheral blood was collected from de-identified platelet transfusion filters from donors according to IRB-approved protocol.
  • PBMCs were separated by Ficoll and spun at 800 xg for 25 minutes to purify
  • lymphocytes were washed twice with complete RPMI, and 2 x 10 7 cells were resuspended in 5 mL with 10 pL of 200 pg/mL of peptide libraries encompassing IE1 and PP65. Cells were incubated at 37°C for 1 hour. Five mL of complete media was added and 100,000 cells/well were plated in 96-well round-bottom plates. Cytokines were added at the indicated concentration in a final volume of 200 LLL. Cells were cultured for seven days. Plates were then spun down at 400 xg and the cells re-suspended in 200 pL of complete media.
  • Plates were spun down at 400 xg for 5 minutes and re-suspended in 100 pL of complete media containing the mix of IE1 and PP65 peptide libraries at 1.0 pg/mL final concentration with no peptide controls. Cells were incubated with peptides at 37°C for 1 hour. Then, 100 pL of complete media containing Brefeldin A or Monensin was added. Cells were cultured for an additional 5 hours, after which cells were stained with antibodies for phenotyping.
  • ELISPOT plates were coated with 100 pL of 1 pg/mL final concentration anti-IFNy mAb (Clone 1-DlK; Mabtech, Cincinnati, OH) in sterile ELISPOT carbonate coating buffer (1.59 g Na 2 C0 3 , 2.93 g NaHC0 3 per liter of sterile water) overnight at 4°C. Plates were washed twice with 150 pL of coating buffer, and 100 pL of complete media was added to wells and incubated for 1 hour at 37°C. Cells from G-rexlO culture vessels were plated at the indicated
  • Cells were spun down at 400 xg for 5 minutes and washed once in 100 pL lx PBS. Cells were spun down again and re-suspended in 50 pL of lx PBS containing Live Dead Aqua at a dilution of 1:500 and then stained for 20 minutes at 4°C, and washed with 100 pL of lx PBS containing 2% FCS.
  • Markers for staining included CD62L V450 (Biolegend; clone DREG-56), CD4 BV570 (Biolegend; clone RPA-T4), CD45RO BV605 (Biolegend; clone UCHL1), CD8 BV711 (Biolegend; clone SKI), CD56 BV785 (Biolegend; clone 5.1H11), CCR7 FITC (Biolegend; G043H7), CD28 PE (Miltenyi Biotec, San Diego, CA; clone REA612) , CD95 PE Dazzle CF594 (Biolegend; clone DX2),
  • CD3 PerCP Cy5.5 (Biolegend; clone OKT3), TNFa PE Vio770 (Miltenyi Biotec; clone cA2), IFNy APC (Biolegend; clone RS.B3), CD107a APC H7 (Miltenyi Biotec; clone REA 792), CD45RA APC H7 (Biolegend; clone HI100).
  • Cells were stained for at least 30 minutes at 4°C then washed twice with 100 pL of lx Permwash and re-suspended in 55 pL of lx Permwash.
  • the method allowed for up to 40 cytokine culture conditions to be tested on 1 x 10 7 PBMCs in a 96 well plate using the IQue Screener Plus high throughput screener for all flow cytometry.
  • This method combined initial culturing and antigen specific expansion with staining and analysis in a single culture plate (FIG. 1).
  • Flow cytometry was selected as the method for analysis to combine measurements of cellular phenotype, viability, expansion, and effector function in a single 13-color panel.
  • To test for antigen specificity cells were split on day 7 into two identical plates with fresh media and cytokines, and plates were subsequently challenged with or without peptide pools on day 10.
  • Combinations of IL15, IL6, IL21, and IFNa were initially selected as compared against IL4 and IL7 as a reference standard for four samples (plate layouts 1, 2; FIG. 2A and 2B). Modified layouts which added IL12 and IL18, as well as combinations intermixing IL15, IL6, IL4 and IL7, were also tested. Furthermore, layouts with additional replicates of IL15 + IL6 and IL4 + IL7, and replicates challenged with irrelevant peptide pools as an additional measure of antigen specificity were tested (plate layouts 3, 4;
  • FIG. 2C and 2D show the use of 96 well plates as both culture and staining vessels for flow cytometric analysis allowed testing of 92 different combinations of cytokines using four different plate layouts.
  • the workflow for analysis of samples utilized a hierarchical gating strategy which categorized positive and negative gates based on initial FMO staining controls as analyzed within Flowjo (FIG. 3). For phenotyping, the frequency of living CD3+, CD3+ CD4+, and CD3+ CD8+ T cells present within the culture was measured, along with CD3- CD56+ NK cells.
  • T cell memory markers were used to judge the differentiation status of cells, including CD45RA, CD45RO, CCR7, CD28, CD95, and CD62L.
  • FIG. 5A Representative heat map data are shown FIG. 5A and summarized in FIG 4.
  • Control culture of PBMCs without added cytokine did not support T cell growth.
  • CD3+ T cell expansion in the standard cytokine mix of IL4 and IL7 achieved a 12.3 -fold increase over control.
  • IL15 alone or in combination with other cytokines achieved the best expansions at the highest dose of 10 ng/mL representing a 22.5-fold increase over control.
  • Mixtures containing IL6 and IL21 produced only a modest expansion of 2.9-fold.
  • IL15 10 ng/mL
  • IL6 100 ng/mL
  • FIG. 5B It was confirmed that addition of IL15 or IL7 was sufficient for expansion of CD3+ T cells, and that the original selection of IL15/IL6 was superior to all other combinations.
  • culture in a combination of IL15/IL6 consistently promoted CD3+ T cell expansion and IFNy production to levels similar to culture in IL4/IL7.
  • CD3- CD56+ NK cells were present in cultures expanded with IL15/IL6, with a median of 6.6% of total cells recovered (4106 cells; FIG. 6A). Less than 300 NK cells were recovered on average from wells containing IL4/IL7, representing 0.6% of total cells recovered.
  • Both culture conditions expanded CD3+ T cells producing IFNy in response to CMV peptide pool re-stimulation.
  • the proportion of multi-cytokine producing cells was also investigated, as evidence suggests these cells offer superior protection against viral infection when compared with cells producing a single cytokine.
  • VSTs that were more skewed towards a CD8+ phenotype.
  • VSTs are effector memory in phenotype
  • T cell differentiation has been suggested to influence the persistence of adoptively transferred T cells [27, 28]
  • Pre-culture CD3+ T cells comprised on average 32% nai ' ve/stem cell memory cells, 30.4% effector memory cells, 22% central memory cells and 15.4% terminal effectors.
  • Ten-day VST products had a preponderance of effector-memory CD3+ cells representing 72.3% and 76.9% of cells grown in IL4/IL7 and IL15/IL6, respectively.
  • Terminal effector cells lacking both CCR7 and CD45RO represented 11.3% in IL4/IL7, and 14.3% in IL15/IL6.
  • Central memory cells represented a minority of cells after culture, 9.3% and 6.6% in IL4/IL7 and IL15/IL6 cultures, respectively.
  • the memory phenotype of antigen specific cells was also compared with antigen non-responsive cells.
  • CD3+ IFNy+ cells had a predominantly effector memory phenotype, while a small number of naive cells (4.2% in IL4/IL7 and 1.7% in
  • IL15/IL6 remained within the IFN-g negative (antigen non-reactive) fraction, suggesting that culture in IL4/IL7 was preserving a subset of naive cells within the final product.
  • VSTs antigen-specific T cells
  • Grex-10 devices which limits the systematic testing of an array of cytokines and growth conditions. Expanding and testing VSTs using such methods requires approximately 20 hours of work and 34 hours of incubation per cytokine condition. In contrast, process development in 96 well plates and a 13 color flow cytometry panel required only 12 hours of work and 8 hours of incubation. To evaluate 40 cytokine conditions would therefore take 2160 hours per sample by existing methods, but only 20 hours using the improved approach disclosed herein (Table 5).
  • IL15/IL6 cultures in Grex-10 culture vessels would recapitulate the data from the experiments in 96-well plates. At least 1 x 10 7 cells were seeded with IE1 and pp65 peptide pools in Grex-10 culture vessels with medium and either IL4/IL7 at 400 U/'rnL IL4/100 ng/mL IL7 or 10 ng/rnL IL15/ 100 ng/mL IL6 (FIG. 8).
  • Cells grown in IL15/IL6 produced a mean of 638 ⁇ 297 spots per 100,000 cells in response to CMV peptides, while cells cultured in IL4 and IL7 produced a mean of 555 ⁇ 230 spots per 100,000 added cells in response to CMV peptide pool re-stimulation.
  • the CMV response was antigen specific, as cells produced less than 10 spots on average in response to either actin or no peptide controls per 100,000 added cells. This demonstrated that cells grown in IL15/IL6 were functionally equivalent to cells grown in IL4/IL7 when cultured to clinical scale and that the high throughput screening method can reliably optimize product development. 4. Discussion
  • a high throughput flow cytometric assay to rapidly and efficiently evaluate growth of viral-specific T cells from donor PBMCs in multiple cytokine combinations was described.
  • superior and comparable expansion and T cell effector function for cells cultured in IL4/IL7 and IL15/IL6 was identified.
  • Culture with IL4/IL7 favored expansion of CD4+ T cells, at the expense of CD8+ T cells, while culture with IL15/IL6 expanded both CD8+ and CD4+ T cells. It was subsequently confirmed that the IL15/IL6 cytokine growth condition was equivalent to IL4/IL7 by IFNy at clinical scales.
  • Cytokine combinations of IL6, IFNa, and IL21 not including IL15 were excluded because they induced little CD3+ proliferation when compared with combinations of IL4 and IL7.
  • IL7 and IL4 in combination with other cytokines it was found that IL7 but not IL4 promoted VST growth. This is consistent with observations that IL4 promotes cell survival but only supports growth of naive T cells [5, 6, 29]
  • IL-6 improved cell expansion in combination with IL15 without modifying effector function. These results are consistent with knockout mouse experiments showing that IL6 reduces the threshold for TCR signaling in CD8+ T cells [30], promoting memory T cell expansion in response to antigen specific peptide re-stimulation.
  • the requirement for including IL-15 or IL-7 for memory T cell expansion is not unexpected as both receptors share homology with IL2 and use the common g-chain and its associated Jak/STAT signaling proteins [31-33]
  • Recombinant IL7 has been used clinically to expand T cell subsets in cases of lymphopenia [34, 35], and was included with IL4 for its pro-survival benefits for T cells [36]
  • CD8+ T cells responses correlate with resolution of disease after HSCT [38], while addition of CMV specific CD4+ T cells has also been demonstrated to help CD8+ T cell responses for some HSCT patients [39], and has been suggested to support CD8+ cell persistence [40] While the data here show a bias towards expanding CD4+ T cells in products cultured with IL4/IL7.
  • VST cells cultured in IL4/IL7 to treat ongoing viral infections, including EBV related post transplant lymphoproliferative disorder (PTLD) [41-44]
  • PTLD EBV related post transplant lymphoproliferative disorder
  • IL15/IL6 may provide a more balanced ratio of antigen specific CD4+ to CD8+ T cells during polyclonal expansion of T cell products against not only viral specific antigens, but also other targets, including tumor-associated antigens.
  • this high throughput plate-based flow cytometric assay was shown to be able to effectively and reliably measure T cell growth, function, and phenotype to optimize VST product development.
  • the data here show that IL15/IL6 is equivalent to IL4/IL7 in GMP culture conditions.
  • the modular nature of the assay facilitates future investigations to optimize culture conditions with 3 or 4 cytokine combinations using IL15/IL6 and IL4/IL7 as a baseline.
  • IL6, IL4, and IL-7 While no or limited improvement in T cell effector numbers were stimulated with IL18 or IL12 for CD3 expansion or extra IFNy production by the T cells.
  • a combination of IL18 with IL6 or the combination of IL12 with IL6 did not expand CD3+ T cells at all.
  • a combination of IL18 with IL15, IL4, or IL7 or IL-12 with IL15, IL4, or IL7 did expand CD3+ T cell populations. Both data points suggest that IL-18 with IL-15 may expand effector T cell population but at least that substitution of IL18 or IL12 did not improve the expansion or effector cytokine production.
  • SARS-CoV-2-specific T cells were expanded from the peripheral blood of 23 convalescent donors by stimulation with peptides spanning the SARS-CoV-2 envelope, membrane, nucleocapsid, and spike antigens.
  • membrane, spike, and nucleocapsid peptides elicited IFN-g production, in 12 (52%), 6 (26%), and 4 (17%) convalescent donors (respectively), and in none of 11 unexposed controls.
  • Multiple novel CD4-restricted epitopes were identified within membrane protein, which induced polyfunctional T cell responses critical for the development of effective vaccine and T cell therapies.
  • SARS-CoV-2 a novel coronavirus first reported in December 2019 from Wuhan, China, is responsible for the ongoing pandemic of coronavirus disease 2019 (COVID-19)[46]
  • the adaptive immune response to SARS-CoV-2 remains ill-defined, and there is an urgent need to fill this gap in knowledge in order to enable the development of effective vaccines and therapies.
  • antibody responses to the spike and nucleocapsid proteins are well described [45, 47], the characterization of T cell response to SARS-CoV-2 is still limited.
  • T cell epitopes within conserved regions of SARS-CoV-2 stmctural proteins are presented. These predominately comprise MHC- Il-restricted CD4+ T cell responses, similar to those observed in response to other respiratory viruses.
  • SARS-CoV-2 in concert with humoral immunity, this study advances our understanding of the overall adaptive immune response to SARS-CoV- 2, facilitating the development of both adoptive T cell therapies and of effective vaccines for the treatment of individuals at risk of infection.
  • PBMCs Peripheral blood mononuclear cells
  • CSTs SARS-CoV-2-specific T cells
  • Evaluated T cell products included SARS-CoV-2 specific T cells, manufactured from PBMCs of seropositive and seronegative volunteers. VSTs were produced using a rapid expansion protocol previously described. Briefly, PBMCs were pulsed with overlapping peptide pools encompassing viral antigens (1 pg 715 x 10 6 PBMCs) for 30 minutes at 37°C. Peptide libraries of 15-mers with 11 amino acids overlaps encompassing the spike, membrane, nucleocapsid, and envelope proteins were generated (A&A peptide, San Diego, CA, USA) from the SARS-CoV-2 reference sequence (NC_045512.2).
  • IL-4 400 IU/ml; R&D Systems, Minneapolis, MN
  • IL-7 10 ng/ml; R&D Systems
  • CTL media consisting of 45% RPMI (GE Healthcare, Logan, UT), 45% Click’s medium (Irvine Scientific, Santa Ana, CA), 10% fetal bovine semm, and supplemented with 2 mM GlutaMax (Gibco, Grand Island, NY). Cytokines were replenished on day 7. On day 10, cells were harvested and evaluated for antigen specificity and functionality.
  • T cells Antigen specificity of T cells was measured by IFN-g ELISpot (Millipore, Burlington, MA). T cells were plated at 1 c 10’/w ell with no peptide, actin (control), or each of the individual SARS-CoV-2 pepmixes (200 ng/peptide/well). Plates were sent for IFN-g spots forming cells (SFC) counting (Zellnet Consulting, Fort Lee, NJ). iv. Flow Cytometry
  • VSTs were stained with fluorophore-conjugated antibodies against CD4, CD8, TCRap. TCRyb, and CD56.
  • Cytofix/Cytoperm solution (BD Biosciences) and stained with IFNy, TNFa, and IL-2 antibodies (Miltenyi Biotec). Data was analyzed with FlowJo X (FlowJo LLC, Ashland, OR;
  • Cut-off limits for determining positive antibodies in the SARS-CoV-2- infected samples were based on the mean plus three standard deviations of the serum values derived from uninfected blood donor controls or by receiver operator characteristics (ROC) analysis. For some of the data percentages for categorical variables, mean and range, geometric mean plus 95% Cl were used to describe the data. Wilcoxon signed rank were used for statistical analysis.
  • T-cell and humoral responses measured here represent an effective adaptive immune response to SARS-CoV-2.
  • Subjects were not tested longitudinally, and therefore the absence of T-cell responses in 30% of subjects may relate to the timing of T- cell responses following primary infection. Evaluation was limited to structural viral proteins, given their described immunodominance in related coronaviruses, but it is possible that T-cell responses to non-structural proteins may also occur.
  • Example 2 Using the methods and materials disclosed in Example 1, the following data were observed.
  • IL15 supported survival of CD3+ T cells when used at the highest dose of 10 ng/mL in combination with other cytokines including IL6, IL21, or IFNa.
  • Culture of PBMCs without additional cytokine did not support T cell growth, with a mean of only 2432 viable CD3+ cells recovered.
  • Culture of PBMCs in IL15 alone induced substantial T cell growth, with an average of 54,788 viable CD3+ T cells recovered the top dilution of 10 ng/mL of IL15, representing a 22.5-fold increase over wells without cytokine.
  • CD3+ T cell expansion was also significantly reduced in wells with lower
  • IL15 concentrations of IL15 regardless of the presence of additional cytokines IL6, IL21, or IFNa. Also, culture with IL6, IL21, or IFNa alone was not sufficient to stimulate T cell expansion in the absence of IL15.
  • CD3+ T cell expansion in the presence of IL4 and IL7 400 U/mL and 10 ng/mL was less than seen with cells cultured in IL15 for this sample, with an average of 29,998 CD3+ cells recovered (12.3-fold increase over no cytokine controls).
  • Lower concentrations of IL4 + IL7 reduced the expansion of CD3+ T cells, as 7837 cells were recovered on average (3.2- fold increase) in culture with 16 U/mL IL4 and 0.4 ng/mL IL7.
  • Intermixing IL6, IL21, and IFNa did not produce appreciable CD3+ expansion, with the greatest expansion found in wells cultured in IL21 and IL6 (7002 cells for 100 ng/mL each; a 2.9-fold increase), however this amount was still substantially below wells cultured in the presence of IL15 or IL4/IL7.
  • the combination of IL15 (10 ng/mL) and IL6 (100 ng/mL) was selected for further investigation based on the favorable expansion of CD3+ T cells and their cytokine production as seen in four of the samples tested compared with other cytokine combinations (FIG. 17).
  • the plate layout was further modified to investigate additional replicates of IL15 and IL6, new cytokine combinations with IL12 and IL18 while removing IL21 and IFNa cytokines, and new combinations of IL4, IL15, IL6, and IL7 with each other (FIG. 19).
  • IL4/IL7 Culture in IL4/IL7 expanded 14.0-fold more CD3+ cells on average compared with no cytokine controls (FIG. 18A; 38,838 vs 2755 cells). Viability of CD3+ cells on average was not significantly different between wells containing IL15/IL6 or IL4/IL7, averaging 90% and 89%, respectively.
  • NK cells were present in cultures expanded with IL15 + IL6, averaging 3878 cells, which was 6.2% of total cells recovered (FIG. 18A). Less than 300 NK cells were recovered on average from wells containing IL4/IL7, representing 0.6% of total cells recovered.
  • Both culture conditions expanded CD3+ T cells which produced IFNy in response to CMV peptide re-stimulation.
  • An average of 24% of CD8+ T cells produced IFNy in response to antigenic peptide in wells cultured in the highest concentration of IL15+IL6, while
  • T cells produced as cellular therapy products are effector memory in phenotype
  • IL4 can be preserving a large fraction of non-specific CD4+ T cells within final products.
  • surface expression of markers associated with T cell memory in addition to intracellular cytokine staining was measured as part of the comprehensive panel. Cells were stained with antibodies specific for CCR7 and CD45RO as primary indicators of memory, along with CD95, CD28, and CD45RA to investigate how the different cytokine combinations affected the evolution of memory in the products.
  • Pre-culture naive/stem cell memory cells comprised 32% of CD3+ T cells on average, with effector memory cells comprising the next highest fraction with 30.4% of cells on average.
  • Central memor cells were 22% of the CD3+ population on average, and terminal effectors were the smallest fraction of CD3+ T cells on average (15.4%).
  • Further analysis of CD4+ and CD8+ subsets identified helper and cytotoxic specific staining patterns as shown in one representative sample. For this sample, 44% of CD4+ T cells displayed a naive/stem cell memory phenotype (CCR7+ CD45RO-) compared with 13% of CD8+ T cells.
  • CD4+ T cells were also central memory (37%; CCR7+ CD45RO+) than effector memoiy (18%; CCR7- CD45RO+).
  • CD8+ T cells reversed this pattern, with 27% of cells displaying an effector memory phenotype compared with 9% displaying central memory phenotype.
  • less than 1% of CD4+ T cells were terminal effectors (CCR7- CD45RO-), while 51% of CD8+ T cells were terminal effectors.
  • the memory phenotype of antigen specific cells and antigen non-responsive cells within the same well was determined by I FNy production in response to peptide.
  • CD3+ IFNy+ cells were also predominantly effector memory in phenotype, while a small but recurrent fraction of naive cells were identified within the antigen non-reactive fraction (IFN-g negative) in cells cultured with IL4 and IL7 (4.2%) which was lower than when cells were grown in IL15 and IL6 (1.7%).
  • IFN-g negative antigen non-reactive fraction
  • the IL15 receptor is a heterotrimer composed of the IL2R ⁇ 1, the common g-chain, and the specific IL15Ra, while the IL7 receptor is a heterodimer consisting of the common g-chain with IL7Ra/CD127.
  • Recombinant IL7 had been previously used clinically to expand T cell subsets in cases of lymphopenia, and was included with IL4 for its pro-survival benefits for T cells.
  • IL4 had been described to support T cell survival by inhibiting degradation of anti-apoptotic factors Bcl2 and Bcl-xL, while IL4 induced proliferation was more limited to naive cells.
  • the data also demonstrated that addition of IL6 to IL15 improved the total CD3+ and CD8+ expansion, while showing no significant difference for effector function compared with IL15 alone.
  • Initial experiments in knockout mice previously demonstrated that IL6 was not required for survival of naive cells.
  • signaling via IL6 has been described to reduce the threshold for TCR signaling in CD8+ T cells, which aligns with the data and would be ideal for promoting memory T cell expansion in response to peptide re-stimulation.
  • CD8+ T cells responses correlate with resolution of disease after HSCT, while addition of CMV specific CD4+ T cells has also been demonstrated to help CD8+ T cell responses for some HSCT patients.
  • IL15/IL6 can provide a more balanced ratio of antigen specific CD4+ to CD8+ T cells during polyclonal expansion of T cell products against not only viral specific antigens, but also other targets, including tumor associated antigens.
  • VST products grown in either 96 well plates or G-rex vessels were CCR7- CD45RO+ CD45RA- CD62L-, nominally effector memory, when cultured with either IL4/IL7 or IL15/IL6. Cytokine combinations which produced a substantial frequency of either central memory cells, or stem cell memory cells were not identified. Culture in IL4 promoted survival of a naive CD4+ population which was absent in cultures with IL15/IL6.
  • lymphocytes in gas-permeable flasks to numbers needed for patient treatment J Immunother 35(3) (2012) 283-92.
  • A.M. Leen, et al. Multicenter study of banked third-part ⁇ ' virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation, Blood 121(26) (2013) 5113- 23. 26.
  • A.M. Leen, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals, Nature medicine 12(10) (2006) 1160-6.
  • CMV cytomegalovirus
  • SARS-CoV-2 T-cell immunity is directed against the spike, membrane, and nucleocapsid protein and associated with COVID 19 severity. medRxiv (2020).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés de culture et d'expansion de lymphocytes T CD4+ et/ou CD8+ en culture. Dans certains modes de réalisation, les procédés comprennent l'expansion, la prolifération et le stockage de lymphocytes dans une culture tissulaire en exposant des lymphocytes à une combinaison de cytokines et/ou d'acides nucléiques exprimant des cytokines (ou des fragments fonctionnels ou des variants correspondants). L'invention concerne en outre des procédés de génération et de fabrication de lymphocytes T CD4+ et/ou CD8+ qui sont spécifiques à un ou plusieurs antigènes viraux.
PCT/US2020/035618 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Ceased WO2020243729A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20814747.0A EP3976068A4 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t
US17/537,816 US20220160767A1 (en) 2019-05-31 2021-11-30 Cytokine cocktails for selective expansion of t cell subsets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855889P 2019-05-31 2019-05-31
US62/855,889 2019-05-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/049902 Continuation-In-Part WO2022056285A1 (fr) 2019-05-31 2021-09-10 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/537,816 Continuation-In-Part US20220160767A1 (en) 2019-05-31 2021-11-30 Cytokine cocktails for selective expansion of t cell subsets

Publications (1)

Publication Number Publication Date
WO2020243729A1 true WO2020243729A1 (fr) 2020-12-03

Family

ID=73553344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/035618 Ceased WO2020243729A1 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Country Status (2)

Country Link
EP (1) EP3976068A4 (fr)
WO (1) WO2020243729A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114578048A (zh) * 2021-12-22 2022-06-03 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
WO2022125746A3 (fr) * 2020-12-09 2022-08-04 Tevogen Bio Inc. Lymphocytes t spécifiques d'un virus et procédés de traitement et de prévention d'infections virales
WO2022195120A1 (fr) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Procédé d'analyse directe de l'avidité fonctionnelle de lymphocytes t
WO2022212505A1 (fr) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Production optimale de particules pseudovirales (vlp) du sars-cov-2 produites dans des cellules de mammifère
WO2023034958A1 (fr) * 2021-09-03 2023-03-09 Dupont Nutrition Biosciences Aps Antigènes microbiens à réactivité croisée destinés à être utilisés dans la stimulation de lymphocytes t
CN116694828A (zh) * 2023-08-01 2023-09-05 北京大学人民医院 检测试剂的应用、cd3+t细胞抗感染能力评估方法及产品
GR1010557B (el) * 2022-05-04 2023-10-16 Νοσοκομειο Γεωργιος Παπανικολαου, Sars-cov-2-ειδικα τ λεμφοκυτταρα για θεραπεια της covid-19
US12104178B2 (en) 2017-03-03 2024-10-01 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12343379B2 (en) 2017-09-06 2025-07-01 Yale University Interleukin-18 variants and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154228A1 (en) * 2011-06-11 2014-06-05 Hans-Dieter Volk Antigen-specific central-memory t cell preparations having high cd4+ fraction
US20160333314A1 (en) * 2015-05-13 2016-11-17 Terumo Bct, Inc. Cell Expansion
WO2018005712A1 (fr) * 2016-06-28 2018-01-04 Geneius Biotechnology, Inc. Compositions de lymphocytes t pour immunothérapie
WO2018081318A1 (fr) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines de spicule de coronavirus de préfusion et utilisation associée
US20190144826A1 (en) * 2009-08-24 2019-05-16 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4089167A1 (fr) * 2012-02-09 2022-11-16 Baylor College of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
EP3350600A4 (fr) * 2015-09-18 2019-04-17 Baylor College of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
CN114231486A (zh) * 2015-10-30 2022-03-25 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190144826A1 (en) * 2009-08-24 2019-05-16 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US20140154228A1 (en) * 2011-06-11 2014-06-05 Hans-Dieter Volk Antigen-specific central-memory t cell preparations having high cd4+ fraction
US20160333314A1 (en) * 2015-05-13 2016-11-17 Terumo Bct, Inc. Cell Expansion
WO2018005712A1 (fr) * 2016-06-28 2018-01-04 Geneius Biotechnology, Inc. Compositions de lymphocytes t pour immunothérapie
WO2018081318A1 (fr) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines de spicule de coronavirus de préfusion et utilisation associée

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERDEMANN ET AL.: "Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant", J VIS EXP, vol. 51, 27 May 2011 (2011-05-27), pages 1 - 6, XP055034564, DOI: 10.3791/2736 *
See also references of EP3976068A4 *
YANG ET AL.: "Long-lived effector/central memory T- cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients", CLIN IMMUNO L, vol. 120, 16 June 2006 (2006-06-16), pages 171 - 178, XP028652192, DOI: 10.1016/j.clim.2006.05.002 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12104178B2 (en) 2017-03-03 2024-10-01 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12343379B2 (en) 2017-09-06 2025-07-01 Yale University Interleukin-18 variants and methods of use
US12403180B2 (en) 2017-09-06 2025-09-02 Yale University Interleukin-18 variants and methods of use
WO2022125746A3 (fr) * 2020-12-09 2022-08-04 Tevogen Bio Inc. Lymphocytes t spécifiques d'un virus et procédés de traitement et de prévention d'infections virales
WO2022195120A1 (fr) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Procédé d'analyse directe de l'avidité fonctionnelle de lymphocytes t
WO2022212505A1 (fr) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Production optimale de particules pseudovirales (vlp) du sars-cov-2 produites dans des cellules de mammifère
WO2023034958A1 (fr) * 2021-09-03 2023-03-09 Dupont Nutrition Biosciences Aps Antigènes microbiens à réactivité croisée destinés à être utilisés dans la stimulation de lymphocytes t
CN114578048A (zh) * 2021-12-22 2022-06-03 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
CN114578048B (zh) * 2021-12-22 2023-08-08 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
GR1010557B (el) * 2022-05-04 2023-10-16 Νοσοκομειο Γεωργιος Παπανικολαου, Sars-cov-2-ειδικα τ λεμφοκυτταρα για θεραπεια της covid-19
CN116694828A (zh) * 2023-08-01 2023-09-05 北京大学人民医院 检测试剂的应用、cd3+t细胞抗感染能力评估方法及产品

Also Published As

Publication number Publication date
EP3976068A1 (fr) 2022-04-06
EP3976068A4 (fr) 2023-08-09

Similar Documents

Publication Publication Date Title
EP3976068A1 (fr) Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t
JP7485385B2 (ja) 適応型の表現型を示すｎｋ細胞ならびにその製造方法および使用方法
EP3263595A1 (fr) Protéine de fusion pour une utilisation dans le traitement de maladie hvg
WO2017077096A1 (fr) Composition destinée à être utilisée en immunothérapie
US20240293452A1 (en) Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
EP4251177A2 (fr) Lymphocytes t spécifiques d'un antigène et méthodes de fabrication et d'utilisation associées
US20230210902A1 (en) Sars-cov-2-specific t cells
AU2009214980B2 (en) Methods of obtaining antigen-specific T cell populations
US20230149459A1 (en) V delta1+ t cells for the treatment of myeloid malignancies
US20250352570A1 (en) Methods for treating myeloid malignancies
WO2022056285A1 (fr) Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t
US20220160767A1 (en) Cytokine cocktails for selective expansion of t cell subsets
EP4171586B1 (fr) Cellules t cd4+ polydonatrices exprimant l'il-10 et leur utilisation
KR20210011937A (ko) 미코박테리아 항원 조성물 및 사용 방법
CN112972491B (zh) 癌症治疗或预防用细胞组合物、及其制造方法
US20250288667A1 (en) Genetically engineered mucosal-associated invariant t (mait) cells for adoptive transfer celltherapy
CN113249331B (zh) 负载Tax抗原的DC细胞、CTL细胞及其制备方法和应用
WO2024209429A1 (fr) Lymphocytes t destinés à être utilisés dans le traitement de la leucémie myéloïde aiguë récidivante ou réfractaire
WO2025122569A1 (fr) Récepteur de lymphocytes t spécifique du néoantigène kmt2a::aff1 et son utilisation en immunothérapie adoptive
Zanon Stem cell-like properties of memory T cells in human immune reconstitution
Stadler Dissecting ALK-specific CD4 T Cell Responses for ALK-positive Anaplastic Large Cell Lymphoma Immunotherapy
CN113564116A (zh) 特异性抗病毒过继免疫细胞ce的制备方法
CN119708263A (zh) 一种靶向cd38且分泌il-15的car-t细胞及其制备方法
EA048854B1 (ru) V дельта1+ т-клетки для лечения миелоидных злокачественных новообразований
Pallan Investigating T cell immunity against the oncogenic Merkel cell polyomavirus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20814747

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020814747

Country of ref document: EP

Effective date: 20220103